id,x_name,x_type,x_source,x_external_source_id,relation,relation_name,y_name,y_type,y_source,y_external_source_id,source_type,source_link,source_date
397,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_STAGE,,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
398,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_STAGE,,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
399,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_STAGE,,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
400,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,1,Cognitive Stimulation Therapy,Therapy,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
401,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,1,Reminiscence Therapy,Therapy,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
402,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_THERAPY,1,Behavioral Management,Therapy,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
403,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,,Music Therapy,Therapy,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
404,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,,Difficulty learning new information,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
405,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,,Subtle language problems,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
406,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,,Significant memory loss,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
407,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,,Confusion in daily activities,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
408,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,,Behavioral changes,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
409,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,,Severe memory loss,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
410,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,,Complete dependence on others,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
411,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_PHENOTYPES,,Physical symptoms,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
412,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
413,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
414,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
415,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
416,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
417,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
418,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
419,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
420,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_TREATMENT,,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
421,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/4834/smpc,2023/1/15
422,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/4835/smpc,2023/1/15
423,Rivastigmine Patch Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/7766/smpc,2023/1/15
424,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/1271/smpc,2023/1/15
425,Galantamine Treatment moderate hepatic impairment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/1271/smpc,2023/1/15
426,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/8222/smpc,2023/1/15
427,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/8222/smpc,2023/1/15
428,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/8222/smpc,2023/1/15
429,Memantine Treatment renal impairment 3 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/8222/smpc,2023/1/15
430,Haloperidol Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/10907/smpc,2023/1/15
431,Risperidone Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Electronic Medicines Compendium,es_14,SR,https://www.medicines.org.uk/emc/product/4353/smpc,2023/1/15
432,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,1,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
433,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
434,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_STEP,,Donepezil Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
435,Donepezil Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,,Donepezil 5mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
436,Donepezil 5mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,,1 month,Duration,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
437,Donepezil Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,,Donepezil Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
438,Donepezil Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,,Donepezil 10mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
439,Donepezil Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_POPULATION,,increased if tolerated and necessary,Population,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
440,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EFFECTIVENESS,,Significant improvement in cognitive scores and daily activities,Effectiveness,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
441,Donepezil Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
442,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,1,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
443,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
444,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_STEP,,Galantamine Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
445,Galantamine Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,,Galantamine 8mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
446,Galantamine 8mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,,4 week,Duration,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
447,Galantamine Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,,Galantamine Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
448,Galantamine Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,,Galantamine 16mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
449,Galantamine 16mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,,least 4 week,Duration,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
450,Galantamine Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,,Galantamine Treatment (NICE) (3),Step,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
451,Galantamine Treatment (NICE) (3),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,,Galantamine 16-24mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
452,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
453,Galantamine Treatment moderate hepatic impairment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
454,Galantamine Treatment moderate hepatic impairment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_STEP,,Galantamine Treatment moderate hepatic impairment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
455,Galantamine Treatment moderate hepatic impairment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,,Galantamine 8mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
456,Galantamine 8mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,,1 week,Duration,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
457,Galantamine Treatment moderate hepatic impairment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,,Galantamine Treatment moderate hepatic impairment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
458,Galantamine Treatment moderate hepatic impairment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,,Galantamine 8-16mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
459,Galantamine 8-16mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,,4 week,Duration,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
460,Galantamine Treatment moderate hepatic impairment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,,moderate hepatic impairment,Population,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
461,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
462,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,,Rivastigmine 1.5-6.0 twice daily,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
463,Rivastigmine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
464,Rivastigmine Patch Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,,Rivastigmine Patch,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
465,Rivastigmine Patch Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_STEP,,Rivastigmine Patch Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
466,Rivastigmine Patch Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,,Rivastigmine Patch 4.6mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
467,Rivastigmine Patch 4.6mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,,4 week,Duration,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
468,Rivastigmine Patch Treatment (NICE) (1),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,,Rivastigmine Patch Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
469,Rivastigmine Patch Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,,Rivastigmine Patch 9.5mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
470,Rivastigmine Patch 9.5mg/day,Dosage,National Institute for Health and Care Excellence,es_20,DOSAGE_DURATION,,6 week,Duration,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
471,Rivastigmine Patch Treatment (NICE) (2),Step,National Institute for Health and Care Excellence,es_20,STEP_STEP,,Rivastigmine Patch Treatment (NICE) (3),Step,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
472,Rivastigmine Patch Treatment (NICE) (3),Step,National Institute for Health and Care Excellence,es_20,STEP_DOSAGE,,Rivastigmine Patch 13.3mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
473,Rivastigmine Patch Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
474,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,1,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
475,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,,Memantine,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
476,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,,Memantine 5-20 mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
477,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EFFECTIVENESS,,Significant improvement in cognitive decline and behavioral symptoms,Effectiveness,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
478,Memantine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
479,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,1,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
480,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,,Memantine,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
481,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,,Memantine 10-20 mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
482,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EFFECTIVENESS,,Significant improvement in cognitive decline and behavioral symptoms,Effectiveness,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
483,Memantine Treatment renal impairment 1 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,,eGFR is 30–49 mL/minute/1.73 m²,Population,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
484,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,1,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
485,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,,Memantine,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
486,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,,Memantine 10 mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
487,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_EFFECTIVENESS,,Significant improvement in cognitive decline and behavioral symptoms,Effectiveness,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
488,Memantine Treatment renal impairment 2 (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_POPULATION,,eGFR is 5 - 29 mL/minute/1.73 m²,Population,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
489,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,1,Haloperidol Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
490,Haloperidol Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
491,Haloperidol Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,,Haloperidol 0.5-5 mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
492,Haloperidol Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,,no more than 6 weeks,Duration,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
493,Alzheimer Disease,Disease,National Institute for Health and Care Excellence,es_20,DISEASES_TREATMENT,1,Risperidone Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
494,Risperidone Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,DRUG_TREATMENT,,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
495,Risperidone Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,,Risperidone 0.5-5 mg/day,Dosage,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
496,Risperidone Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,TREATMENT_DOSAGE,,no more than 6 weeks,Duration,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
497,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Nausea,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
498,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
499,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Anorexia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
500,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
501,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Muscle cramps,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
502,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Syncope,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
503,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Headache,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
504,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
505,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Abnormal dreams,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
506,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hallucinations,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
507,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Agitation,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
508,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Aggression,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
509,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Urinary incontinence,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
510,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Rash,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
511,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Pruritus,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
512,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Extrapyramidal symptoms,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
513,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Sinoatrial block,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
514,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Atrioventricular (AV) block,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
515,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Liver dysfunction (including hepatitis),SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
516,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Neuroleptic malignant syndrome (NMS),SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
517,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Fatigue,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
518,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Insomnia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
519,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
520,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Nausea,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
521,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Abdominal pain,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
522,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Diarrhoea,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
523,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dyspepsia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
524,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Decreased appetite,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
525,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Weight loss ,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
526,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Bradycardia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
527,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hypertension,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
528,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Syncope,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
529,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hallucinations,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
530,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Depression,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
531,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
532,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Tremor,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
533,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Headache,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
534,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Fatigue,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
535,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Malaise,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
536,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Muscle spasm,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
537,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Retching,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
538,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dehydration,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
539,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hypotension,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
540,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Flushing,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
541,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Palpitation,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
542,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Arrhythmias,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
543,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,First-degree AV block,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
544,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Taste disturbance,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
545,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Paraesthesia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
546,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Seizures,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
547,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hypersomnia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
548,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Muscular weakness,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
549,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Blurred vision,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
550,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Tinnitus,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
551,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Sweating,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
552,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Exacerbation of Parkinson's disease,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
553,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hepatitis,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
554,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Serious skin reactions,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
555,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Nausea,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
556,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
557,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Diarrhoea,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
558,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dyspepsia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
559,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Anorexia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
560,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Weight loss,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
561,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Abdominal pain,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
562,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Bradycardia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
563,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
564,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Headache,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
565,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Drowsiness,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
566,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Gait abnormalities,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
567,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Fall,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
568,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Malaise,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
569,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Agitation,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
570,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Anxiety,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
571,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Tremor,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
572,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Confusion,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
573,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Insomnia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
574,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Parkinsonism,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
575,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Syncope,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
576,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Skin reactions,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
577,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Urinary tract infection,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
578,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Urinary incontinence,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
579,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Sweating,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
580,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Atrial fibrillation,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
581,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,AV block,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
582,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Depression,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
583,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Aggression,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
584,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Extrapyramidal symptoms,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
585,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Gastric and duodenal ulceration,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
586,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Pancreatitis,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
587,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Angina,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
588,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Seizures,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
589,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dehydration,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
590,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hallucinations,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
591,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hepatitis,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
592,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Restlessness,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
593,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Sick sinus syndrome,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
594,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Tachycardia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
595,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hypertension,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/acetylcholinesterase-inhibitors/,2024/4/1
596,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Constipation,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
597,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hypertension,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
598,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dyspnoea,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
599,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Headache,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
600,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
601,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Impaired balance,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
602,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Drowsiness,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
603,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
604,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Thrombosis,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
605,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Heart failure,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
606,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Confusion,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
607,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Fatigue,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
608,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hallucinations,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
609,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Abnormal gait,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
610,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Seizures,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
611,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Pancreatitis,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
612,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Psychosis,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
613,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Depression,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
614,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Suicidal ideation,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/memantine-hydrochloride/,2024/4/1
615,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Extrapyramidal symptoms,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
616,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Weight gain,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
617,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dyslipidaemia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
618,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hyperprolactinaemia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
619,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Sedation,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
620,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Sleep apnoea syndrome,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
621,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Anticholinergic effects,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
622,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Postural hypotension,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
623,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hypertension,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
624,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Reduced seizure threshold,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
625,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Impaired glucose tolerance,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
626,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,"Cardiomyopathy, myocarditis, and cutaneous vasculitis",SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
627,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,QT interval prolongation,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
628,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Stroke risk,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
629,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Venous thromboembolism (VTE),SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
630,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Neuroleptic malignant syndrome (NMS),SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
631,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Pneumonia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
632,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Neutropenia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
633,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Abnormal liver function tests (LFTs),SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
634,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Photosensitivity,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
635,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Skin and subcutaneous tissue disorders,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
636,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Diplopia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
637,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Misuse and abuse,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
638,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Restless legs syndrome,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
639,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Extrapyramidal symptoms,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
640,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Weight gain,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
641,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Dyslipidaemia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
642,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hyperprolactinaemia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
643,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Sedation,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
644,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Sleep apnoea syndrome,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
645,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Anticholinergic effects,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
646,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Postural hypotension,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
647,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Hypertension,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
648,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Reduced seizure threshold,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
649,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Impaired glucose tolerance,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
650,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,"Cardiomyopathy, myocarditis, and cutaneous vasculitis",SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
651,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,QT interval prolongation,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
652,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Stroke risk,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
653,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Venous thromboembolism (VTE),SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
654,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Neuroleptic malignant syndrome (NMS),SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
655,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Pneumonia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
656,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Neutropenia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
657,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Abnormal liver function tests (LFTs),SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
658,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Photosensitivity,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
659,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Skin and subcutaneous tissue disorders,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
660,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Diplopia,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
661,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Misuse and abuse,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
662,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_SIDE_EFFECT,,Restless legs syndrome,SideEffect,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/prescribing-information/antipsychotics/,2024/4/1
663,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_THERAPY,,Cognitive Stimulation Therapy,Therapy,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
664,Mild (MMSE 21-26),Stage,National Institute for Health and Care Excellence,es_20,STAGE_THERAPY,,Reminiscence Therapy,Therapy,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
665,Moderate (MMSE 10-20),Stage,National Institute for Health and Care Excellence,es_20,STAGE_THERAPY,,Behavioral Management,Therapy,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
666,Severe (MMSE <10),Stage,National Institute for Health and Care Excellence,es_20,STAGE_THERAPY,,Music Therapy,Therapy,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
667,Cognitive Stimulation Therapy,Therapy,National Institute for Health and Care Excellence,es_20,THERAPY_EFFECTIVENESS,,Improves memory attention and social interaction,Effectiveness,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/,2024/4/1
668,Reminiscence Therapy,Therapy,National Institute for Health and Care Excellence,es_20,THERAPY_EFFECTIVENESS,,Helps maintain long-term memory improves mood,Effectiveness,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/,2024/4/1
669,Behavioral Management,Therapy,National Institute for Health and Care Excellence,es_20,THERAPY_EFFECTIVENESS,,Reduces anxiety and agitation improves daily functioning,Effectiveness,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/,2024/4/1
670,Music Therapy,Therapy,National Institute for Health and Care Excellence,es_20,THERAPY_EFFECTIVENESS,,Improves mood reduces agitation provides positive emotions,Effectiveness,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/management/follow-up-of-confirmed-dementia-in-primary-care/,2024/4/1
671,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe cardiac arrhythmia,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
672,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Pregnancy and breastfeeding.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
673,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"Known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipients used in the formulation",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
674,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"History of bradycardia, heart block, recurrent unexplained syncope.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
675,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Concurrent treatment with drugs that reduce heart rate.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
676,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Sick sinus syndrome or other supraventricular conduction abnormalities.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
677,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Susceptibility to peptic ulcers including concurrent nonsteroidal anti inflammatory (NSAID) use.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
678,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Asthma and chronic obstructive pulmonary disease (COPD).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
679,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Hepatic impairment. ,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
680,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Concomitant antipsychotic treatment — increased risk of neuroleptic malignant syndrome (NMS).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
681,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Concomitant antipsychotic treatment — increased risk of neuroleptic malignant syndrome (NMS).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
682,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Hypersensitivity to galantamine or to any of the excipients.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
683,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe renal impairment (estimated glomerular filtration rate [eGFR] less than 9 mL/minute/1.73 m²).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
684,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe hepatic impairment (Child-Pugh score greater than 9).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
685,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,People who have both significant renal and hepatic dysfunction.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
686,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Urinary outflow obstruction.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
687,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Gastrointestinal obstruction.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
688,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,During recovery from bladder or gastrointestinal surgery.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
689,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Pregnancy and breastfeeding.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
690,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Renal and hepatic impairment.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
691,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"Cardiac disease or in those who use medicinal products that significantly reduce heart rate concomitantly, such as digoxin and beta blockers.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
692,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,QTc interval prolongation or taking drugs that prolong the QTc interval.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
693,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Electrolyte disturbances (such as hyperkalaemia or hypokalaemia).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
694,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"Susceptibility to peptic ulcers, including concomitant use of NSAIDs.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
695,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"History of severe asthma, COPD, or pulmonary infection.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
696,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,History of seizures.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
697,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"Known hypersensitivity to rivastigmine, other carbamate derivatives, or to any of the excipients used in the formulation.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
698,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Previous history of application site reactions suggestive of allergic contact dermatitis with the rivastigmine patch.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
699,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Pregnancy and breastfeeding.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
700,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Hepatic impairment.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
701,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Renal impairment.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
702,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Gastric or duodenal ulcers (or susceptibility to ulcers).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
703,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Sick sinus syndrome or conduction abnormalities.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
704,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,History of asthma or COPD.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
705,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,History of seizures.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
706,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Bladder outflow obstruction.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
707,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"Pre-existing, or a family history of, QT interval prolongation.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
708,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Higher risk of developing torsade de pointes,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
709,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"Hypersensitivity to the active substance or to any of the excipients, including people with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
710,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe hepatic impairment.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
711,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe renal impairment — memantine hydrochloride should be avoided if the estimated glomerular filtration rate (eGFR) is less than 5 mL/minute/1.73 m².,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
712,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,History of convulsions or predisposing factors for epilepsy. ,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
713,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe renal impairment,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
714,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"Central nervous system depression, comatose states.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
715,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"Congenital long QT syndrome, history of Torsade de Pointes, QTc interval",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
716,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"prolongation, concurrent use with drugs that prolong the QT interval, history of",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
717,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"ventricular arrhythmias, recent myocardial infarction, uncompensated heart failure.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
718,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Uncorrected hypokalaemia.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
719,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Progressive supranuclear palsy.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
720,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Dementia with Lewy bodies.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
721,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Parkinson's disease.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
722,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Blood dyscrasias.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
723,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"Cardiovascular disease — an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, personal history of cardiovascular disease.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
724,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Conditions predisposing to seizures.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
725,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Depression.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
726,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Diabetes (may raise blood glucose).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
727,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Epilepsy.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
728,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,History of jaundice.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
729,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Myasthenia gravis.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
730,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Parkinsonʼs disease (may be exacerbated).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
731,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Photosensitization (may occur with higher dosages).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
732,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Prostatic hypertrophy.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
733,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe respiratory disease.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
734,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Susceptibility to angle-closure glaucoma,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
735,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Bradycardia.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
736,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Uncorrected electrolyte disturbances.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
737,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Family history of QTc-interval prolongation.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
738,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,History of heavy alcohol exposure.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
739,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Hyperthyroidism.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
740,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Hypotension (including orthostatic hypotension).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
741,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Prolactin-dependent tumours.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
742,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Prolactinaemia.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
743,Haloperidol,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Risk factors for stroke.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
744,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Hypersensitivity to risperidone or to any of the excipients.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
745,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Acute porphyrias.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
746,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Cataract surgery (risk of intra-operative floppy iris syndrome).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
747,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Dehydration.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
748,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Dementia with Lewy bodies.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
749,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Prolactin-dependent tumours.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
750,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Blood dyscrasias.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
751,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,"Cardiovascular disease — an ECG may be required, particularly if physical examination identifies cardiovascular risk factors, personal history of cardiovascular disease.",Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
752,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Conditions predisposing to seizures.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
753,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Depression.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
754,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Diabetes (may raise blood glucose).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
755,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Epilepsy.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
756,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,History of jaundice.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
757,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Myasthenia gravis.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
758,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Parkinsonʼs disease (may be exacerbated).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
759,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Photosensitization (may occur with higher dosages).,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
760,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Prostatic hypertrophy.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
761,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe respiratory disease.,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
762,Risperidone,Drug,National Institute for Health and Care Excellence,es_20,DRUG_PHENOTYPES_CONTRAINDICATION,,Susceptibility to angle-closure glaucoma,Phenotypes,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
763,Galantamine Treatment (NICE),Treatment,National Institute for Health and Care Excellence,es_20,MONITORING_TREATMENT,,Weight monthly,Monitoring,National Institute for Health and Care Excellence,es_20,Guideline,https://cks.nice.org.uk/topics/dementia/,2024/4/1
764,Alzheimer Disease,Disease,成大指引,es_19,DISEASES_STAGE,,初期,Stage,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
765,Alzheimer Disease,Disease,成大指引,es_19,DISEASES_STAGE,,中期,Stage,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
766,Alzheimer Disease,Disease,成大指引,es_19,DISEASES_STAGE,,晚期,Stage,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
767,Alzheimer Disease,Disease,成大指引,es_19,DISEASES_TREATMENT,1,Donepezil Treatment (成大),Treatment,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
768,Donepezil Treatment (成大),Treatment,成大指引,es_19,DRUG_TREATMENT,,Donepezil,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
769,Donepezil Treatment (成大),Treatment,成大指引,es_19,TREATMENT_DOSAGE,,起始劑量5 mg/day 每日劑量  5-10 mg/day,Dosage,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
770,Alzheimer Disease,Disease,成大指引,es_19,DISEASES_TREATMENT,1,Rivastigmine Treatment (NICE),Treatment,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
771,Rivastigmine Treatment (成大),Treatment,成大指引,es_19,DRUG_TREATMENT,,Rivastigmine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
772,Rivastigmine Treatment (成大),Treatment,成大指引,es_19,TREATMENT_DOSAGE,,起始劑量: 3mg/day 每日劑量  6-12 mg/day,Dosage,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
773,Alzheimer Disease,Disease,成大指引,es_19,DISEASES_TREATMENT,1,Galantamine  Treatment (NICE),Treatment,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
774,Galantamine Treatment (成大),Treatment,成大指引,es_19,DRUG_TREATMENT,,Galantamine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
775,Galantamine Treatment (成大),Treatment,成大指引,es_19,TREATMENT_DOSAGE,,起始劑量: 8mg/day 每日劑量   8-24 mg/day,Dosage,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
776,Galantamine Treatment (成大),Treatment,成大指引,es_19,TREATMENT_DURATION,,每日兩次持續四週,Duration,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
777,Alzheimer Disease,Disease,成大指引,es_19,DISEASES_TREATMENT,1,Memantine Treatment (NICE),Treatment,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
778,Memantine Treatment (成大),Treatment,成大指引,es_19,DRUG_TREATMENT,,Memantine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
779,Memantine Treatment (成大),Treatment,成大指引,es_19,TREATMENT_DOSAGE,,起始劑量: 5 mg/day 每日劑量   5-20mg/day,Dosage,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
780,Donepezil,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Nausea,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
781,Donepezil,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
782,Donepezil,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Insomnia,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
783,Donepezil,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
784,Donepezil,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Muscle cramps,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
785,Donepezil,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Fatigue,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
786,Donepezil,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,decreased appetite,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
787,Rivastigmine Patch,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Headache,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
788,Rivastigmine Patch,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
789,Rivastigmine Patch,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Anxiety,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
790,Rivastigmine Patch,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Nausea,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
791,Rivastigmine Patch,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
792,Rivastigmine Patch,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Insomnia,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
793,Rivastigmine Patch,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
794,Rivastigmine Patch,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Depressed,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
795,Rivastigmine Patch,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Dyspepsia,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
796,Rivastigmine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Nausea,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
797,Rivastigmine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
798,Rivastigmine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
799,Rivastigmine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Anorexia,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
800,Rivastigmine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
801,Galantamine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Nausea,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
802,Galantamine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
803,Galantamine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
804,Galantamine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Anorexia,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
805,Galantamine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
806,Galantamine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Drowsiness,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
807,Galantamine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Anorexia,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
808,Galantamine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Dyspepsia,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
809,Galantamine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Weight lose,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
810,Memantine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Headache,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
811,Memantine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
812,Memantine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Drowsiness,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
813,Memantine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
814,Memantine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Hallucination,SideEffect,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
815,Memantine,Drug,成大指引,es_19,DRUG_SIDE_EFFECT,,Myalgia,SideEffect,成大指引,es_19,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
816,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
817,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
818,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
819,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
820,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
821,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_STAGE,,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
822,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",Phenotypes,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
823,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",Phenotypes,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
824,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,,"Difficulties with basic activities of daily living (e.g. feeding,dressing).",Phenotypes,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
825,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,,"Difficulties with instrumental activities of daily living (e.g. housework, managing money).",Phenotypes,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
826,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,,Fully dependent,Phenotypes,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
827,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_PHENOTYPES,,Fully dependent,Phenotypes,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
828,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
829,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
830,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
831,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
832,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
833,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
834,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
835,Mild  (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
836,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
837,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
838,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
839,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
840,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
841,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
842,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
843,Moderate (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
844,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
845,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
846,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
847,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
848,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
849,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
850,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
851,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
852,Severe (MMSE <10),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
853,Severe (ADAS-Cog),Stage,Ministry of Health Malaysia,es_18,STAGE_TREATMENT,,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021/1/1
854,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,Cochrane Library,es_10,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021/1/1
855,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,Cochrane Library,es_10,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021/1/1
856,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,Cochrane Library,es_10,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021/1/1
857,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,Cochrane Library,es_10,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2021/1/1
858,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_EVIDENCE_LEVEL,,Moderate to Low quality,Evidence,Cochrane Library,es_10,SR,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
859,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_TREATMENT,1,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
860,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DRUG_TREATMENT,,Donepezil,Drug,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
861,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_DOSAGE,,5 mg/day for 12-24 week,Dosage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
862,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_DOSAGE,,10 mg/day for 24-26 week,Dosage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
863,Donepezil Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26) (ADAS-Cog),Population,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
864,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_TREATMENT,1,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
865,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DRUG_TREATMENT,,Rivastigmine,Drug,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
866,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_DOSAGE,,6 - 12 mg/day twice daily 26 week,Dosage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
867,Rivastigmine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26) (ADAS-Cog),Population,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
868,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_TREATMENT,1,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
869,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DRUG_TREATMENT,,Rivastigmine Patch,Drug,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
870,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_DOSAGE,,9.5 mg/day patch 26 week,Dosage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
871,Rivastigmine Patch Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26) (ADAS-Cog),Population,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
872,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_TREATMENT,1,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
873,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DRUG_TREATMENT,,Galantamine,Drug,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
874,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_DOSAGE,,24 mg/day 21-26 week,Dosage,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
875,Galantamine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26) (ADAS-Cog),Population,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
876,Alzheimer Disease,Disease,Ministry of Health Malaysia,es_18,DISEASES_TREATMENT,1,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
877,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,DRUG_TREATMENT,,Memantine,Drug,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
878,Memantine Treatment (MaHTAS),Treatment,Ministry of Health Malaysia,es_18,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20) (ADAS-Cog),Population,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
879,Donepezil,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Nausea,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
880,Donepezil,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
881,Donepezil,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
882,Rivastigmine,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Nausea,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
883,Rivastigmine,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
884,Rivastigmine,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
885,Rivastigmine Patch,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Nausea,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
886,Rivastigmine Patch,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
887,Rivastigmine Patch,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
888,Memantine,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Nausea,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
889,Memantine,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
890,Memantine,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
891,Memantine,Drug,Ministry of Health Malaysia,es_18,DRUG_SIDE_EFFECT,,Mortality,SideEffect,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
892,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_THERAPY,,Exercise,Therapy,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
893,Mild (MMSE 21-26),Stage,Ministry of Health Malaysia,es_18,STAGE_THERAPY,,Diet and supplement,Therapy,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
894,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_THERAPY,,Exercise,Therapy,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
895,Moderate (MMSE 10-20),Stage,Ministry of Health Malaysia,es_18,STAGE_THERAPY,,Diet and supplement,Therapy,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
896,Exercise,Therapy,Ministry of Health Malaysia,es_18,THERAPY_EFFECTIVENESS,,Aerobic exercise is known to have cognition-enhancing effects,Effectiveness,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
897,Diet and supplement,Therapy,Ministry of Health Malaysia,es_18,THERAPY_EFFECTIVENESS,,"Improvements in performance, particularly in memory",Effectiveness,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
898,Cognitive enhancing therapy,Therapy,Ministry of Health Malaysia,es_18,THERAPY_EFFECTIVENESS,,"Improve and maintain cognitive function, thus reducing the progression of cognitive deterioration.",Effectiveness,Ministry of Health Malaysia,es_18,Guideline,https://www.acadmed.org.my/view_file.cfm?fileid=1021,2021/1/1
899,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
900,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
901,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
902,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Galantamine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
903,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
904,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
905,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
906,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Galantamine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
907,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
908,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
909,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
910,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Galantamine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
911,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Memantine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
912,Severe (MMSE <10),Stage,American Academy of Family Physicians,es_1,STAGE_TREATMENT,,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full,2006/1/1
913,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_10,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full,2015/1/1
914,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_10,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full,2015/1/1
915,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_10,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub2/full,2004/1/1
916,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_10,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub2/full,2004/1/1
917,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_10,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub5/full,2006/1/1
918,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_10,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub5/full,2006/1/1
919,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_10,SR,https://jamanetwork.com/journals/jama/fullarticle/1810379#google_vignette,2014/1/1
920,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EVIDENCE_LEVEL,,High quality (Level B),Evidence,Cochrane Library,es_10,SR,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
921,Alzheimer Disease,Disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,1,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
922,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,,Donepezil,Drug,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
923,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,,Donepezil Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
924,Donepezil Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,5 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
925,5 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 to 6 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
926,Donepezil Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Donepezil Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
927,Donepezil Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,10 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
928,10 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,3 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
929,Donepezil Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Donepezil Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
930,Donepezil Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,23 mg at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
931,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,,improvement in global function and cognitive symptoms,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
932,Donepezil Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
933,Alzheimer Disease,Disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,1,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
934,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,,Rivastigmine,Drug,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
935,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
936,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,1.5 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
937,1.5 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,2 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
938,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
939,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,3 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
940,3 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,2 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
941,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
942,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,4.5 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
943,4.5 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,2 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
944,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
945,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,6 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
946,6 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,2 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
947,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (5),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
948,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (5),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,7.5 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
949,7.5 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,2 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
950,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (5),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (6),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
951,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (6),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,9 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
952,9 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,2 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
953,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (6),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (7),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
954,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (7),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,10.5 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
955,10.5 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,2 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
956,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (7),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (7),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
957,Rivastigmine Treatment (AmericanAcademy of Family Physicians) (8),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,12 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
958,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_DOSAGE,,"1.5 mg orally 2 times per day for 2 weeks, then increase each dose in 1.5-mg increments every 2 weeks as tolerated to maximal dosage of 12 mg per day",Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
959,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,,improvement in global function and cognitive symptoms,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
960,Rivastigmine Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
961,Alzheimer Disease,Disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,1,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
962,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,,Rivastigmine Patch,Drug,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
963,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
964,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,4.6-mg patch every 24 hours,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
965,4.6-mg patch every 24 hours,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
966,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
967,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,9.5-mg patch every 24 hours,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
968,9.5-mg patch every 24 hours,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
969,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
970,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,13.3-mg patch every 24 hours,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
971,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,,improvement in global function and cognitive symptoms,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
972,Rivastigmine Patch Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
973,Alzheimer Disease,Disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,1,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
974,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,,Galantamine,Drug,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
975,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
976,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,4 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
977,4 mg orally 2 times per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
978,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
979,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,8 mg 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
980,8 mg 2 times per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
981,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
982,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,12mg 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
983,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,,improvement in global function and cognitive symptoms,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
984,Galantamine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
985,Alzheimer Disease,Disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,1,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
986,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,,Galantamine,Drug,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
987,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
988,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,8 mg orally per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
989,8 mg orally per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
990,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
991,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,16 mg per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
992,16 mg per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
993,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
994,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,24 mg per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
995,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,,improvement in global function and cognitive symptoms,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
996,Galantamine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
997,Alzheimer Disease,Disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,1,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
998,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,,Memantine,Drug,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
999,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1000,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,5 mg orally per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1001,5 mg orally per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,1 week,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1002,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1003,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,5 mg 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1004,5 mg 2 times per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,1 week,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1005,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1006,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,10 mg every morning and 5mg every night,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1007,10 mg every morning and 5mg every night,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,1 week,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1008,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1009,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,10 mg 2 times per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1010,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,,improvement in global function and cognitive symptoms,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1011,Memantine Immediate Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1012,Alzheimer Disease,Disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,1,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1013,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,,Memantine,Drug,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1014,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1015,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,7 mg orally per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1016,7 mg orally per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,1 week,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1017,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1018,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,14 mg orally per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1019,14 mg orally per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,1 week,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1020,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1021,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,21 mg orally per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1022,21 mg orally per day,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,1 week,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1023,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1024,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,28 mg orally per day,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1025,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,,improvement in global function and cognitive symptoms,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1026,Memantine Extended Release Treatment (AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1027,Alzheimer Disease,Disease,American Academy of Family Physicians,es_1,DISEASES_TREATMENT,1,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1028,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,,Donepezil,Drug,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1029,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,,Memantine,Drug,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1030,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,DRUG_TREATMENT,,Vitamin E,Drug,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1031,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_STEP,,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1032,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,Memantine:7 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1033,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,Donepezil: 10 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1034,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,"Vitamin E:1,000 IU orally 2 times per day",Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1035,Memantine:7 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1036,Donepezil: 10 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1037,"Vitamin E:1,000 IU orally 2 times per day",Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1038,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (1),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1039,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,Memantine:14 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1040,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,Donepezil: 10 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1041,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,"Vitamin E:1,000 IU orally 2 times per day",Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1042,Memantine:14 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1043,Donepezil: 10 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1044,"Vitamin E:1,000 IU orally 2 times per day",Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1045,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (2),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1046,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,Memantine:21 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1047,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,Donepezil: 10 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1048,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,"Vitamin E:1,000 IU orally 2 times per day",Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1049,Memantine:21 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1050,Donepezil: 10 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1051,"Vitamin E:1,000 IU orally 2 times per day",Dosage,American Academy of Family Physicians,es_1,DOSAGE_DURATION,,4 weeks,Duration,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1052,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (3),Step,American Academy of Family Physicians,es_1,STEP_STEP,,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1053,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,Memantine:28 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1054,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,Donepezil: 10 mg orally at bedtime,Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1055,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians) (4),Step,American Academy of Family Physicians,es_1,STEP_DOSAGE,,"Vitamin E:1,000 IU orally 2 times per day",Dosage,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1056,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_EFFECTIVENESS,,improvement in global function and cognitive symptoms,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1057,Combination Drug and Vitamin E(AmericanAcademy of Family Physicians),Treatment,American Academy of Family Physicians,es_1,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1058,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Atrioventricular block,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1059,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Decreased appetite,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1060,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1061,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Hypertension,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1062,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Syncope,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1063,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1064,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Weight loss,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1065,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1066,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Headache,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1067,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Nausea,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1068,Donepezil,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Torsades de pointes,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1069,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Abdominal pain,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1070,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Atrial fibrillation,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1071,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Atrioventricular block,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1072,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Decreased appetite,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1073,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1074,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Headache,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1075,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Infarction,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1076,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1077,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1078,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Myocardial,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1079,Rivastigmine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Nausea,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1080,Galantamine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Atrioventricular block,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1081,Galantamine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Decreased appetite,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1082,Galantamine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1083,Galantamine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Headache,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1084,Galantamine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1085,Galantamine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1086,Galantamine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Nausea,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1087,Galantamine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Weight loss,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1088,Memantine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1089,Memantine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1090,Memantine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Decreased appetite,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1091,Memantine,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Heart block,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1092,Vitamin E,Drug,American Academy of Family Physicians,es_1,DRUG_SIDE_EFFECT,,Hemorrhage,SideEffect,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1093,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,,Enjoyable leisure activities,Therapy,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1094,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,,Mental stimulation programs,Therapy,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1095,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,,Occupational therapy training in coping strategies and cognitive aides,Therapy,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1096,Mild (MMSE 21-26),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,,Structured physical exercise programs,Therapy,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1097,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,,Enjoyable leisure activities,Therapy,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1098,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,,Mental stimulation programs,Therapy,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1099,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,,Occupational therapy training in coping strategies and cognitive aides,Therapy,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1100,Moderate (MMSE 10-20),Stage,American Academy of Family Physicians,es_1,STAGE_THERAPY,,Structured physical exercise programs,Therapy,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1101,Enjoyable leisure activities,Therapy,American Academy of Family Physicians,es_1,THERAPY_EFFECTIVENESS,,Improves memory attention and social interaction,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1102,Mental stimulation programs,Therapy,American Academy of Family Physicians,es_1,THERAPY_EFFECTIVENESS,,Helps maintain long-term memory improves mood,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1103,Occupational therapy training in coping strategies and cognitive aides,Therapy,American Academy of Family Physicians,es_1,THERAPY_EFFECTIVENESS,,Reduces anxiety and agitation improves daily functioning,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/1
1104,Structured physical exercise programs,Therapy,American Academy of Family Physicians,es_1,THERAPY_EFFECTIVENESS,,Improves mood reduces agitation provides positive emotions,Effectiveness,American Academy of Family Physicians,es_1,Guideline,https://www.aafp.org/pubs/afp/issues/2017/0615/p771.pdf,2017/1/2
1105,Alzheimer Disease,Disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_STAGE,,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1106,Alzheimer Disease,Disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_STAGE,,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1107,Alzheimer Disease,Disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_STAGE,,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1108,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,,Memory loss for recent events,Phenotypes,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1109,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,,Difficulty learning new information,Phenotypes,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1110,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,,Subtle language problems,Phenotypes,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1111,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,,Significant memory loss,Phenotypes,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1112,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,,Confusion in daily activities,Phenotypes,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1113,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,,Behavioral changes,Phenotypes,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1114,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,,Severe memory loss,Phenotypes,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1115,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,,Complete dependence on others,Phenotypes,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1116,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_PHENOTYPES,,Physical symptoms,Phenotypes,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1117,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,,Donepezil Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1118,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,,Rivastigmine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1119,Mild (MMSE 21-26),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,,Galantamine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1120,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,,Donepezil Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1121,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1122,Moderate (MMSE 10-20),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,,Galantamine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1123,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,,Memantine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1124,Severe (MMSE <10),Stage,The Association of Scientific Medical Societies in Germany,es_4,STAGE_TREATMENT,,Memantine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_1.pdf,2023/11/1
1125,Donepezil Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,pubmed,es_50,SR,https://www.iqwig.de/download/a05-19a_abschlussbericht_cholinesterasehemmer_bei_alzheimer_demenz.pdf,2007/2/7
1126,Rivastigmine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,pubmed,es_50,SR,https://www.iqwig.de/download/a05-19a_abschlussbericht_cholinesterasehemmer_bei_alzheimer_demenz.pdf,2007/2/7
1127,Galantamine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,pubmed,es_50,SR,https://www.iqwig.de/download/a05-19a_abschlussbericht_cholinesterasehemmer_bei_alzheimer_demenz.pdf,2007/2/7
1128,Memantine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,pubmed,es_50,SR,https://www.iqwig.de/download/a05-19a_abschlussbericht_cholinesterasehemmer_bei_alzheimer_demenz.pdf,2007/2/7
1129,Alzheimer Disease,Disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_TREATMENT,1,Donepezil Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_2.pdf,2023/11/1
1130,Donepezil Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,DRUG_TREATMENT,,Donepezil,Drug,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_3.pdf,2023/11/1
1131,Donepezil Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DOSAGE,,5mg daily,Dosage,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_4.pdf,2023/11/1
1132,Donepezil Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DURATION,,Review every 6 months,Duration,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_5.pdf,2023/11/1
1133,Donepezil Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_6.pdf,2023/11/1
1134,Donepezil Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_8.pdf,2023/11/1
1135,Alzheimer Disease,Disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_TREATMENT,1,Galantamine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_9.pdf,2023/11/1
1136,Galantamine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,DRUG_TREATMENT,,Galantamine,Drug,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_10.pdf,2023/11/1
1137,Galantamine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DOSAGE,,8mg daily,Dosage,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_11.pdf,2023/11/1
1138,Galantamine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DURATION,,Review every 6 months,Duration,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_12.pdf,2023/11/1
1139,Galantamine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_13.pdf,2023/11/1
1140,Galantamine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_15.pdf,2023/11/1
1141,Alzheimer Disease,Disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_TREATMENT,1,Memantine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_16.pdf,2023/11/1
1142,Memantine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,DRUG_TREATMENT,,Memantine,Drug,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_17.pdf,2023/11/1
1143,Memantine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DOSAGE,,5mg daily,Dosage,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_18.pdf,2023/11/1
1144,Memantine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DURATION,,Review every 6 months,Duration,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_19.pdf,2023/11/1
1145,Memantine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EFFECTIVENESS,,significant effect on ADL function at 24 weeks,Effectiveness,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_20.pdf,2023/11/1
1146,Memantine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_22.pdf,2023/11/1
1147,Alzheimer Disease,Disease,The Association of Scientific Medical Societies in Germany,es_4,DISEASES_TREATMENT,1,Rivastigmine Treatment (Demenzen),Treatment,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_23.pdf,2023/11/1
1148,Rivastigmine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,DRUG_TREATMENT,,Rivastigmine,Drug,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_24.pdf,2023/11/1
1149,Rivastigmine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DOSAGE,,3mg daily,Dosage,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_25.pdf,2023/11/1
1150,Rivastigmine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_DURATION,,Review every 6 months,Duration,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_26.pdf,2023/11/1
1151,Rivastigmine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_27.pdf,2023/11/1
1152,Rivastigmine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_29.pdf,2023/11/1
1153,Donepezil,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Nausea,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_30.pdf,2023/11/1
1154,Donepezil,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_31.pdf,2023/11/1
1155,Donepezil,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_32.pdf,2023/11/1
1156,Donepezil,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Headache,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_33.pdf,2023/11/1
1157,Donepezil,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_34.pdf,2023/11/1
1158,Donepezil,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Agitation,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_35.pdf,2023/11/1
1159,Rivastigmine,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Gastrointestinal,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_36.pdf,2023/11/1
1160,Memantine,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Agitation,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_37.pdf,2023/11/1
1161,Memantine,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Hypertension,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_38.pdf,2023/11/1
1162,Memantine,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Falls,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_39.pdf,2023/11/1
1163,Memantine,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_40.pdf,2023/11/1
1164,Memantine,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Headache,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_41.pdf,2023/11/1
1165,Galantamine,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Gastrointestinal,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_42.pdf,2023/11/1
1166,Galantamine,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_43.pdf,2023/11/1
1167,Galantamine,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_SIDE_EFFECT,,Headache,SideEffect,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_45.pdf,2023/11/1
1168,Memantine,Drug,The Association of Scientific Medical Societies in Germany,es_4,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe renal impairment,Phenotypes,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_47.pdf,2023/11/1
1169,Donepezil Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,MONITORING_TREATMENT,,Cognitive function (MMSE) every 6 months,Monitoring,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_48.pdf,2023/11/1
1170,Memantine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,MONITORING_TREATMENT,,Cognitive function (MMSE) every 6 months,Monitoring,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_49.pdf,2023/11/1
1171,Rivastigmine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,MONITORING_TREATMENT,,Cognitive function (MMSE) every 6 months,Monitoring,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_50.pdf,2023/11/1
1172,Galantamine Treatment (Germany),Treatment,The Association of Scientific Medical Societies in Germany,es_4,MONITORING_TREATMENT,,Cognitive function (MMSE) every 6 months,Monitoring,The Association of Scientific Medical Societies in Germany,es_4,Guideline,https://register.awmf.org/assets/guidelines/038-013l_S3_Demenzen-2023-11_51.pdf,2023/11/1
1173,Alzheimer Disease,Disease,Cognitive Decline Partnership Centre,es_5,DISEASES_STAGE,,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1174,Alzheimer Disease,Disease,Cognitive Decline Partnership Centre,es_5,DISEASES_STAGE,,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1175,Alzheimer Disease,Disease,Cognitive Decline Partnership Centre,es_5,DISEASES_STAGE,,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1176,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,,short-term memory loss,Phenotypes,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1177,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,,Apathy,Phenotypes,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1178,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,,Depression,Phenotypes,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1179,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,,Significant memory loss,Phenotypes,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1180,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,,Confusion in daily activities,Phenotypes,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1181,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,,Behavioral changes,Phenotypes,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1182,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,,Severe memory loss,Phenotypes,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1183,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,,Complete dependence on others,Phenotypes,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1184,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_PHENOTYPES,,Physical symptoms,Phenotypes,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1185,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1186,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1187,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1188,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1189,Moderate (MMSE 10-20),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1190,Mild (MMSE 21-26),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1191,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1192,Severe (MMSE <10),Stage,Cognitive Decline Partnership Centre,es_5,STAGE_TREATMENT,,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1193,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EVIDENCE_LEVEL,,Low quality (Level C),Evidence,pubmed,es_21,SR,https://pubmed.ncbi.nlm.nih.gov/22541366/,2016/2/1
1194,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,pubmed,es_21,SR,https://pubmed.ncbi.nlm.nih.gov/22541366/,2016/2/1
1195,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,pubmed,es_21,SR,https://pubmed.ncbi.nlm.nih.gov/22541366/,2016/2/1
1196,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_EVIDENCE_LEVEL,,Moderate quality (Level B),Evidence,pubmed,es_21,SR,https://pubmed.ncbi.nlm.nih.gov/22541366/,2016/2/1
1197,Alzheimer Disease,Disease,Cognitive Decline Partnership Centre,es_5,DISEASES_TREATMENT,1,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1198,Donepezil Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,DRUG_TREATMENT,,Donepezil,Drug,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1199,Alzheimer Disease,Disease,Cognitive Decline Partnership Centre,es_5,DISEASES_TREATMENT,1,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1200,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,DRUG_TREATMENT,,Galantamine,Drug,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1201,Galantamine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1202,Alzheimer Disease,Disease,Cognitive Decline Partnership Centre,es_5,DISEASES_TREATMENT,1,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1203,Memantine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,DRUG_TREATMENT,,Memantine,Drug,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1204,Alzheimer Disease,Disease,Cognitive Decline Partnership Centre,es_5,DISEASES_TREATMENT,1,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1205,Rivastigmine Treatment (CDPC),Treatment,Cognitive Decline Partnership Centre,es_5,DRUG_TREATMENT,,Rivastigmine,Drug,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1206,Donepezil,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Nausea,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1207,Donepezil,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1208,Donepezil,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1209,Donepezil,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Headache,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1210,Donepezil,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1211,Donepezil,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Agitation,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1212,Rivastigmine,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Gastrointestinal,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1213,Memantine,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Agitation,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1214,Memantine,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Hypertension,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1215,Memantine,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Falls,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1216,Memantine,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1217,Memantine,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Headache,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1218,Galantamine,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Gastrointestinal,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1219,Galantamine,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1220,Galantamine,Drug,Cognitive Decline Partnership Centre,es_5,DRUG_SIDE_EFFECT,,Headache,SideEffect,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1221,Cognitive stimulation,Therapy,Cognitive Decline Partnership Centre,es_5,THERAPY_EFFECTIVENESS,,Enhancement of cognitive and social functioning,Effectiveness,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1222,Cognitive training,Therapy,Cognitive Decline Partnership Centre,es_5,THERAPY_EFFECTIVENESS,,"Typically involves guided practice on a set of standard tasks designed to reflect particular cognitive functions, such as memory, attention, language or executive function",Effectiveness,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1223,Cognitive rehabilitation,Therapy,Cognitive Decline Partnership Centre,es_5,THERAPY_EFFECTIVENESS,,"Individualised approach to helping people with cognitive impairments in which those affected, and their families, work together with health care professionals to identify personally-relevant goals and devise strategies for addressing these. The emphasis is not on enhancing performance on cognitive tasks but on improving functioning in the everyday context.",Effectiveness,Cognitive Decline Partnership Centre,es_5,Guideline,https://www.nhmrc.gov.au/sites/default/files/documents/attachments/CDPC-Dementia-Guidelines.pdf,2016/2/1
1224,Mild (MMSE 21-26),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Donepezil Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1225,Mild (MMSE 21-26),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Rivastigmine Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1226,Mild (MMSE 21-26),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Rivastigmine Patch Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1227,Mild (MMSE 21-26),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Galantamine Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1228,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Donepezil Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1229,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Rivastigmine Patch Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1230,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Rivastigmine Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1231,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Galantamine Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1232,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Memantine Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1233,Moderate (MMSE 10-20),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Memantine Treatment 腎功能不佳者 (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1234,Severe (MMSE <10),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Donepezil Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1235,Severe (MMSE <10),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Memantine Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1236,Severe (MMSE <10),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Memantine Treatment 腎功能不佳者 (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1237,Severe (MMSE <10),Stage,臺中榮總,es_22,STAGE_TREATMENT,,Combined Donepezil and Memantine Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1238,早期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,記憶障礙,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1239,早期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,語言困難,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1240,早期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,認知能力下降,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1241,早期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,日常生活影響輕微,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1242,早期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,行為改變,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1243,中期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,記憶喪失,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1244,中期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,語言與溝通障礙,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1245,中期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,行為問題,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1246,中期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,定向感障礙,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1247,中期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,功能下降,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1248,晚期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,嚴重記憶喪失,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1249,晚期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,嚴重語言障礙,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1250,晚期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,嚴重行為失控,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1251,晚期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,生活完全依賴他人,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1252,晚期,Stage,臺中榮總,es_22,STAGE_PHENOTYPES,,身體機能退化,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1253,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_TREATMENT,1,Donepezil Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1254,Donepezil Treatment (臺中榮總),Treatment,臺中榮總,es_22,DRUG_TREATMENT,,Donepezil,Drug,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1255,Donepezil Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_STEP,,Donepezil Treatment (臺中榮總) (1),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1256,Donepezil Treatment (臺中榮總) (1),Step,臺中榮總,es_22,STEP_DOSAGE,,Donepezil 5 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1257,Donepezil 5 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,,4-6 week,Duration,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1258,Donepezil Treatment (臺中榮總) (1),Step,臺中榮總,es_22,STEP_STEP,,Donepezil Treatment (臺中榮總) (2),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1259,Donepezil Treatment (臺中榮總) (2),Step,臺中榮總,es_22,STEP_DOSAGE,,Donepezil 5-10 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1260,Donepezil Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_EFFECTIVENESS,,緩解BPSD,Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1261,Donepezil Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1262,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_TREATMENT,1,Rivastigmine Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1263,Rivastigmine Treatment (臺中榮總),Treatment,臺中榮總,es_22,DRUG_TREATMENT,,Rivastigmine,Drug,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1264,Rivastigmine Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_STEP,,Rivastigmine Treatment (臺中榮總) (1),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1265,Rivastigmine Treatment (臺中榮總) (1),Step,臺中榮總,es_22,STEP_DOSAGE,,Rivastigmine 1.5 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1266,Rivastigmine 1.5 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,,4 week,Duration,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1267,Rivastigmine Treatment (臺中榮總) (1),Step,臺中榮總,es_22,STEP_STEP,,Rivastigmine Treatment (臺中榮總) (2),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1268,Rivastigmine Treatment (臺中榮總) (2),Step,臺中榮總,es_22,STEP_DOSAGE,,Rivastigmine 1.5-4.5 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1269,Rivastigmine 1.5 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,,4 week,Duration,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1270,Rivastigmine Treatment (臺中榮總) (2),Step,臺中榮總,es_22,STEP_STEP,,Rivastigmine Treatment (臺中榮總) (3),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1271,Rivastigmine Treatment (臺中榮總) (3),Step,臺中榮總,es_22,STEP_DOSAGE,,Rivastigmine 4.5-6 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1272,Rivastigmine Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1273,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_TREATMENT,1,Rivastigmine Patch Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1274,Rivastigmine Patch Treatment (臺中榮總),Treatment,臺中榮總,es_22,DRUG_TREATMENT,,Rivastigmine Patch,Drug,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1275,Rivastigmine Patch Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_STEP,,Rivastigmine Patch Treatment (臺中榮總) (1),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1276,Rivastigmine Patch Treatment (臺中榮總) (1),Step,臺中榮總,es_22,STEP_DOSAGE,,Rivastigmine Patch 4.6 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1277,Rivastigmine Patch 4.6 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,,4 week,Duration,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1278,Rivastigmine Patch Treatment (臺中榮總) (1),Step,臺中榮總,es_22,STEP_STEP,,Rivastigmine Patch Treatment (臺中榮總) (2),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1279,Rivastigmine Patch Treatment (臺中榮總) (2),Step,臺中榮總,es_22,STEP_DOSAGE,,Rivastigmine Patch 9.5 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1280,Rivastigmine Patch Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1281,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_TREATMENT,1,Galantamine Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1282,Galantamine Treatment (臺中榮總),Treatment,臺中榮總,es_22,DRUG_TREATMENT,,Galantamine,Drug,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1283,Galantamine Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_STEP,,Galantamine Treatment (臺中榮總) (1),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1284,Galantamine Treatment (臺中榮總) (1),Step,臺中榮總,es_22,STEP_DOSAGE,,Galantamine 8 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1285,Rivastigmine Patch 4.6 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,,4 week,Duration,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1286,Galantamine Treatment (臺中榮總) (1),Step,臺中榮總,es_22,STEP_STEP,,Galantamine Treatment (臺中榮總) (2),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1287,Galantamine Treatment (臺中榮總) (2),Step,臺中榮總,es_22,STEP_DOSAGE,,Galantamine 16-24 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1288,Galantamine Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1289,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_TREATMENT,1,Memantine Treatment (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1290,Memantine Treatment (臺中榮總),Treatment,臺中榮總,es_22,DRUG_TREATMENT,,Memantine,Drug,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1291,Memantine Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_STEP,,Memantine Treatment (臺中榮總) (1),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1292,Memantine Treatment (臺中榮總) (1),Step,臺中榮總,es_22,STEP_DOSAGE,,Memantine 5 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1293,Rivastigmine Patch 4.6 mg/day,Dosage,臺中榮總,es_22,DOSAGE_DURATION,,2 week,Duration,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1294,Memantine Treatment (臺中榮總) (1),Step,臺中榮總,es_22,STEP_STEP,,Memantine Treatment (臺中榮總) (2),Step,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1295,Memantine Treatment (臺中榮總) (2),Step,臺中榮總,es_22,STEP_DOSAGE,,Memantine 10 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1296,Memantine Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_EFFECTIVENESS,,減輕躁動症狀,Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1297,Memantine Treatment (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1298,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_TREATMENT,1,Memantine Treatment 腎功能不佳者 (臺中榮總),Treatment,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1299,Memantine Treatment 腎功能不佳者 (臺中榮總),Treatment,臺中榮總,es_22,DRUG_TREATMENT,,Memantine,Drug,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1300,Memantine Treatment 腎功能不佳者 (臺中榮總),Step,臺中榮總,es_22,TREATMENT_DOSAGE,,Memantine 5 mg/day,Dosage,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1301,Memantine Treatment 腎功能不佳者 (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_EFFECTIVENESS,,減輕躁動症狀,Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1302,Memantine Treatment 腎功能不佳者 (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_EFFECTIVENESS,,腎功能不佳者 (Creatinine Clearance 40 - 60 ml/ min/1.73 m2),Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1303,Memantine Treatment 腎功能不佳者 (臺中榮總),Treatment,臺中榮總,es_22,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1304,Donepezil,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Nausea,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1305,Donepezil,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1306,Donepezil,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1307,Donepezil,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Muscle cramps,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1308,Donepezil,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Urinary incontinence,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1309,Donepezil,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Fatigue,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1310,Donepezil,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Insomnia,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1311,Donepezil,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Loss of appetite,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1312,Donepezil,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Syncope,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1313,Donepezil,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Bradycardia,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1314,Rivastigmine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Nausea,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1315,Rivastigmine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1316,Rivastigmine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1317,Rivastigmine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Muscle cramps,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1318,Rivastigmine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Urinary incontinence,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1319,Rivastigmine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Fatigue,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1320,Rivastigmine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Insomnia,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1321,Rivastigmine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Loss of appetite,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1322,Rivastigmine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Syncope,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1323,Rivastigmine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Bradycardia,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1324,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Nausea,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1325,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1326,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1327,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Muscle cramps,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1328,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Urinary incontinence,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1329,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Fatigue,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1330,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Insomnia,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1331,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Loss of appetite,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1332,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Syncope,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1333,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Bradycardia,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1334,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Skin reaction,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1335,Galantamine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Nausea,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1336,Galantamine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1337,Galantamine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1338,Galantamine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Muscle cramps,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1339,Galantamine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Urinary incontinence,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1340,Galantamine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Fatigue,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1341,Galantamine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Insomnia,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1342,Galantamine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Loss of appetite,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1343,Galantamine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Syncope,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1344,Galantamine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Bradycardia,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1345,Memantine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Headache,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1346,Memantine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1347,Memantine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Sedation,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1348,Memantine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Agitation,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1349,Memantine,Drug,臺中榮總,es_22,DRUG_SIDE_EFFECT,,Constipation,SideEffect,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1350,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Reminiscence Therapy,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1351,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Cognitive Activities,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1352,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Music Therapy Groups,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1353,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Art Creation,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1354,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Exercise Groups,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1355,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Reality Orientation Therapy,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1356,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Dance Therapy,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1357,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Horticulture Therapy,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1358,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Aromatherapy,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1359,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Pet Therapy,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1360,Alzheimer Disease,Disease,臺中榮總,es_22,DISEASES_THERAPY,1,Doll Therapy,Therapy,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1361,Reminiscence Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,Sensory Stimulation,Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1362,Cognitive Activities,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,Maintains cognitive functions and slows the rate of decline.,Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1363,Music Therapy Groups,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,"Promotes social participation, improves mood, and fosters interaction and a sense of happiness.",Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1364,Art Creation,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,"Provides sensory stimulation, enhances focus and expression, boosts self-esteem, and improves group interaction.",Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1365,Exercise Groups,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,"Improves physical fitness, balance, and muscle strength, slows cognitive decline, and enhances quality of life.",Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1366,Reality Orientation Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,"Reinforces awareness of time, place, and people, boosts self-esteem, and reduces problematic behaviors.",Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1367,Dance Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,"Improves mood, stimulates brain activity, and enhances life satisfaction",Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1368,Horticulture Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,"Improves mood, stimulates brain activity, and enhances life satisfaction",Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1369,Aromatherapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,"Improves mood, stimulates brain activity, and enhances life satisfaction",Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1370,Pet Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,"Improves mood, stimulates brain activity, and enhances life satisfaction",Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1371,Doll Therapy,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,"Improves mood, stimulates brain activity, and enhances life satisfaction",Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1372,Sensory Stimulation,Therapy,臺中榮總,es_22,THERAPY_EFFECTIVENESS,,"Improves mood, stimulates brain activity, and enhances life satisfaction",Effectiveness,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1373,Donepezil,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe bradycardia,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1374,Donepezil,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,Heart conduction block,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1375,Donepezil,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患對藥物順從性不佳,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1376,Donepezil,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患在使用藥物後智能、精神行為、或生活功能減退速度反較治療前快,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1377,Donepezil,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患對藥物產生無法忍受之副作用,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1378,Rivastigmine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,疾病末期治療已無意義,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1379,Rivastigmine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe bradycardia,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1380,Rivastigmine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,Heart conduction block,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1381,Rivastigmine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患對藥物順從性不佳,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1382,Rivastigmine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患在使用藥物後智能、精神行為、或生活功能減退速度反較治療前快,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1383,Rivastigmine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患對藥物產生無法忍受之副作用,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1384,Rivastigmine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,疾病末期治療已無意義,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1385,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe bradycardia,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1386,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,Heart conduction block,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1387,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患對藥物順從性不佳,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1388,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患在使用藥物後智能、精神行為、或生活功能減退速度反較治療前快,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1389,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患對藥物產生無法忍受之副作用,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1390,Rivastigmine Patch,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,疾病末期治療已無意義,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1391,Galantamine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe bradycardia,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1392,Galantamine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,Heart conduction block,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1393,Galantamine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患對藥物順從性不佳,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1394,Galantamine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患在使用藥物後智能、精神行為、或生活功能減退速度反較治療前快,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1395,Galantamine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患對藥物產生無法忍受之副作用,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1396,Galantamine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,疾病末期治療已無意義,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1397,Memantine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,Impaired renal function (Creatinine clearance < 40 mL/min/1.73m² requires dosage adjustment),Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1398,Memantine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患對藥物順從性不佳,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1399,Memantine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患在使用藥物後智能、精神行為、或生活功能減退速度反較治療前快,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1400,Memantine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,病患對藥物產生無法忍受之副作用,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1401,Memantine,Drug,臺中榮總,es_22,DRUG_PHENOTYPES_CONTRAINDICATION,,疾病末期治療已無意義,Phenotypes,臺中榮總,es_22,Guideline,https://www.vghtc.gov.tw/UploadFiles/WebFiles/NewsFile/Files/c600e046-b490-48cc-b91c-baacd42b5fcf/%E5%8F%B0%E4%B8%AD%E6%A6%AE%E7%B8%BD%E5%A4%B1%E6%99%BA%E7%97%87%E7%96%BE%E7%97%85%E7%85%A7%E8%AD%B7%E5%9C%98%E9%9A%8A%E8%87%A8%E5%BA%8A%E7%85%A7%E8%AD%B7%E8%A8%88%E7%95%AB%E8%A8%BA%E7%99%82%E6%8C%87%E5%BC%95v2.pdf,2023/4/21
1402,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Donepezil Treatment (Alzheimer Society of B.C.),Treatment,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1403,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Rivastigmine Treatment (Alzheimer Society of B.C.),Treatment,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1404,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Galantamine Treatment (Alzheimer Society of B.C.),Treatment,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1405,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Donepezil Treatment (Alzheimer Society of B.C.),Treatment,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1406,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Rivastigmine Treatment (Alzheimer Society of B.C.),Treatment,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1407,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Galantamine Treatment (Alzheimer Society of B.C.),Treatment,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1408,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Memantine Treatment(Alzheimer Society of B.C.),Treatment,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1409,Late stage (GDS 7),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Donepezil Treatment (Alzheimer Society of B.C.),Treatment,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1410,Late stage (GDS 7),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Memantine Treatment (Alzheimer Society of B.C.),Treatment,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1411,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Memory lapses,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1412,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Forgetting familiar names and locations of objects,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1413,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,These lapses typically are not obvious to others,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1414,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Mild Forgetfulness,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1415,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Difficulty learning new things,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1416,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Difficulty concentrating or limited attention span,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1417,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,"Problems with orientation (e.g., getting lost)",Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1418,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,"Communication difficulties (e.g., finding the right word)",Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1419,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Loss or misplacement of valuable objects,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1420,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Difficulty handling problems at work,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1421,Early stage(GDS 2-5),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,"Noticeable issues to family, friends, or co-workers",Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1422,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Some memory loss involving one's personal history,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1423,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,"Difficulty with complex tasks, e.g. managing finances, shopping, travel",Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1424,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Decreased knowledge of current events and recent events,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1425,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,"Impaired ability to perform challenging mental arithmetic, e.g. counting backward from 75 by 7",Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1426,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,"Major gaps in memory, e.g. phone numbers or names of close family members ",Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1427,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Help is needed with day-to-day tasks,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1428,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,"Continued memory loss, e.g. occasionally forgetting the name of a spouse or primary caregiver",Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1429,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,"Loss of awareness of recent events and experiences in their lives, e.g. not remembering what they had for lunch or their child’s graduation",Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1430,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,"Assistance is needed with activities of daily living, e.g. getting dressed, bathing",Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1431,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Difficulties counting,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1432,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,"Personality and emotion changes such as confusion, anxiety, suspiciousness, anger, sadness/depression, hostility, apprehension, delusion and agitation",Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1433,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Obsessions such as repetition of simple activities- Disruption of normal sleep/waking cycle,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1434,Middle stage (GDS 4-6),Stage,Japanese Society of Neurology,es_17,STAGE_PHENOTYPES,,Increasing episodes of incontinen,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1435,Late stage (GDS 7),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Severe cognitive impairment,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1436,Late stage (GDS 7),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Vocabulary becomes limited and verbal abilities eventually disappear,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1437,Late stage (GDS 7),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Loss of ability to walk independently and sit without support,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1438,Late stage (GDS 7),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Help is needed with eating and using the toilet; usually incontinent,Phenotypes,Japanese Society of Neurology,es_17,Guideline,https://alzheimer.ca/en/about-dementia/dementia-treatment-options-developments,2024/1/1
1439,Mild (MMSE 21-26),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1440,Mild (MMSE 21-26),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Rivastigmine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1441,Mild (MMSE 21-26),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Rivastigmine Patch Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1442,Mild (MMSE 21-26),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Galantamine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1443,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1444,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Rivastigmine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1445,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Rivastigmine Patch Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1446,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Galantamine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1447,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1448,Moderate (MMSE 10-20),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1449,Severe (MMSE <10),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1450,Severe (MMSE <10),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1451,Severe (MMSE <10),Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Combined Donepezil and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1452,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_6,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005593/abstract,2017/7/1
1453,Rivastigmine Patch Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_6,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005593/abstract,2017/7/1
1454,Rivastigmine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_6,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005593/abstract,2017/7/1
1455,Galantamine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_6,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005593/abstract,2017/7/1
1456,Combined Donepezil and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,IJN,es_15,SR,https://academic.oup.com/ijnp/article/18/5/pyu115/786398?login=false,2017/7/1
1457,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_EVIDENCE_LEVEL,,High quality (Level A),Evidence,Cochrane Library,es_7,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub5/full,2017/7/1
1458,Alzheimer Disease,Disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,1,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1459,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,,Donepezil,Drug,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1460,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,,Donepezil 10 mg/day,Dosage,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1461,Donepezil Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 0-26),Population,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1462,Alzheimer Disease,Disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,1,Galantamine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1463,Galantamine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,,Galantamine,Drug,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1464,Galantamine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,,Galantamine 24 mg/day,Dosage,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1465,Galantamine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1466,Alzheimer Disease,Disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,1,Rivastigmine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1467,Rivastigmine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,,Rivastigmine,Drug,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1468,Rivastigmine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,,Rivastigmine 6-12 mg/day,Dosage,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1469,Rivastigmine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1470,Alzheimer Disease,Disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,1,Rivastigmine Patch Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1471,Rivastigmine Patch Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,,Rivastigmine Patch,Drug,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1472,Rivastigmine Patch Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,,Rivastigmine Patch 9.5 mg/day,Dosage,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1473,Rivastigmine Patch Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1474,Alzheimer Disease,Disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,1,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1475,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,,Memantine,Drug,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1476,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,,Memantine 20 mg/day,Dosage,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1477,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1478,Alzheimer Disease,Disease,Japanese Society of Neurology,es_17,DISEASES_TREATMENT,1,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1479,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,DRUG_TREATMENT,,Memantine,Drug,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1480,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,,Memantine 28 mg/day,Dosage,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1481,Combined ChEIs and Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_DOSAGE,,Donepezil 5-10 mg/day,Dosage,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1482,Memantine Treatment (Japanese Society of Neurology),Treatment,Japanese Society of Neurology,es_17,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1483,Alzheimer Disease,Disease,Japanese Society of Neurology,es_17,DISEASES_THERAPY,1,Exercise therapy,Therapy,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1484,Alzheimer Disease,Disease,Japanese Society of Neurology,es_17,DISEASES_THERAPY,1,Music therapy,Therapy,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1485,Exercise therapy,Therapy,Japanese Society of Neurology,es_17,THERAPY_EVIDENCE_LEVEL,,Low quality (Level C),Evidence,Cochrane Library,es_8,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006489.pub4/full,2017/7/1
1486,Music therapy,Therapy,Japanese Society of Neurology,es_17,THERAPY_EVIDENCE_LEVEL,,Low quality (Level C),Evidence,Cochrane Library,es_9,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003477.pub2/full,2017/7/1
1487,Exercise therapy,Therapy,Japanese Society of Neurology,es_17,THERAPY_EFFECTIVENESS,,attenuates worsening of physical function and activities of daily living,Effectiveness,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1488,Music therapy,Therapy,Japanese Society of Neurology,es_17,THERAPY_EFFECTIVENESS,,"improving BPSD, including anxiety",Effectiveness,Japanese Society of Neurology,es_17,Guideline,https://www.neurology-jp.org/guidelinem/dementia/documents/guideline2017.pdf,2017/7/1
1489,(MCI) due to Alzheimer's disease,Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Donanemab Treatment (Alzheimer's Association),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1490,(MCI) due to Alzheimer's disease,Stage,Japanese Society of Neurology,es_17,STAGE_TREATMENT,,Lecanemab (Alzheimer's Association),Treatment,Japanese Society of Neurology,es_17,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1491,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Suvorexant,Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1492,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Donanemab Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1493,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Lecanemab (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1494,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1495,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Rivastigmine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1496,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Galantamine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1497,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Suvorexant,Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1498,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1499,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Rivastigmine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1500,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Galantamine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1501,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Memantine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1502,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1503,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1504,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Memantine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1505,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1506,MCI due to Alzheimer's disease,Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,memory loss ,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1507,MCI due to Alzheimer's disease,Stage,Alzheimer's Association,es_3,STAGE_TREATMENT,,cognitive ability loss,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1508,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Difficultly coming up with the right word or name.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1509,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Difficultly remembering names when introduced to new people.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1510,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Having difficulty performing tasks in social or work settings.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1511,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Forgetting material that was just read.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1512,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Losing or misplacing a valuable object.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1513,Early stage(mild),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Experiencing increased trouble with planning or organizing.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1514,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Being forgetful of events or personal history.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1515,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,"Feeling moody or withdrawn, especially in socially or mentally challenging situations.",Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1516,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,"Being unable to recall information about themselves like their address or telephone number, and the high school or college they attended.",Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1517,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Experiencing confusion about where they are or what day it is.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1518,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Requiring help choosing proper clothing for the season or the occasion.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1519,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Having trouble controlling their bladder and bowels.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1520,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,"Experiencing changes in sleep patterns, such as sleeping during the day and becoming restless at night.",Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1521,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Showing an increased tendency to wander and become lost.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1522,Middle stage (moderate),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,"Demonstrating personality and behavioral changes, including suspiciousness and delusions or compulsive, repetitive behavior like hand-wringing or tissue shredding.",Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1523,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Require around-the-clock assistance with daily personal care.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1524,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Lose awareness of recent experiences as well as of their surroundings.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1525,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,"Experience changes in physical abilities, including walking, sitting and, eventually, swallowing",Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1526,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,Have difficulty communicating.,Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1527,Late stage (severe),Stage,Alzheimer's Association,es_3,STAGE_PHENOTYPES,,"Become vulnerable to infections, especially pneumonia.",Phenotypes,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1528,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,1,Donanemab Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1529,Donanemab Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,,Donanemab,Drug,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1530,Donanemab Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,,MCI to Mild Alzheimer's Disease,Population,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1531,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,1,Lecanemab (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1532,Lecanemab (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,,Lecanemab,Drug,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1533,Lecanemab (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,,MCI to Mild Alzheimer's Disease,Population,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1534,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,1,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1535,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,,Donepezil,Drug,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1536,Donepezil Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,,Mild to severe Alzheimer's Disease,Population,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1537,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,1,Rivastigmine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1538,Rivastigmine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,,Rivastigmine,Drug,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1539,Rivastigmine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease,Population,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1540,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,1,Galantamine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1541,Galantamine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,,Galantamine,Drug,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1542,Galantamine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease,Population,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1543,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,1,Memantine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1544,Memantine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,,Memantine,Drug,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1545,Memantine Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease,Population,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1546,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,1,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1547,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,,Memantine,Drug,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1548,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,,Donepezil,Drug,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1549,Memantine + Donepezil (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease,Population,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1550,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,1,Brexpiprazole Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1551,Brexpiprazole Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,,Brexpiprazole,Drug,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1552,Brexpiprazole Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,,Agitation associated with dementia due to Alzheimer's disease,Population,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1553,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_TREATMENT,1,Suvorexant Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1554,Suvorexant Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,DRUG_TREATMENT,,Suvorexant,Drug,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1555,Suvorexant Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,,Insomnia,Population,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1556,Suvorexant Treatment (Alzheimer's Association),Treatment,Alzheimer's Association,es_3,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease,Population,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1557,Donanemab,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,ARIA,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1558,Donanemab,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,headache,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1559,Lecanemab,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Infusion-related reactions,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1560,Lecanemab,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,ARIA,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1561,Lecanemab,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,headache,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1562,Donepezil,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Nausea,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1563,Donepezil,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1564,Donepezil,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Loss of appetite,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1565,Donepezil,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Muscle cramps,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1566,Donepezil,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Increased frequency of bowel movements,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1567,Galantamine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Nausea,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1568,Galantamine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1569,Galantamine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Loss of appetite,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1570,Galantamine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Increased frequency of bowel movements,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1571,Rivastigmine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Nausea,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1572,Rivastigmine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1573,Rivastigmine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Loss of appetite,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1574,Rivastigmine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Increased frequency of bowel movements,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1575,Memantine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,headache,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1576,Memantine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Constipation,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1577,Memantine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Confusion,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1578,Memantine,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1579,Brexpiprazole,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Weight gain,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1580,Brexpiprazole,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Sleepiness,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1581,Brexpiprazole,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1582,Brexpiprazole,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Common cold symptoms,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1583,Brexpiprazole,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Restlessness or feeling like  need to move,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1584,Suvorexant,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Impaired alertness and motor coordination,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1585,Suvorexant,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Worsening of depression or suicidal thinking,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1586,Suvorexant,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Complex sleep behaviors,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1587,Suvorexant,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Sleep paralysis,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1588,Suvorexant,Drug,Alzheimer's Association,es_3,DRUG_SIDE_EFFECT,,Compromised respiratory function,SideEffect,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1589,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_THERAPY,1,Maintain regular times for meals and for going to bed and getting up,Therapy,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1590,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_THERAPY,1,Seek morning sunlight exposure,Therapy,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1591,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_THERAPY,1,"Encourage regular daily exercise, but no later than four hours before bedtime",Therapy,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1592,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_THERAPY,1,"Avoid alcohol, caffeine and nicotine",Therapy,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1593,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_THERAPY,1,Treat any pain,Therapy,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1594,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_THERAPY,1,"If the person is taking a cholinesterase inhibitor (tacrine, donepezil, rivastigmine or galantamine), avoid giving the medicine before bed",Therapy,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1595,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_THERAPY,1,Make sure the bedroom temperature is comfortable,Therapy,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1596,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_THERAPY,1,Provide nightlights and security objects,Therapy,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1597,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_THERAPY,1,"If the person awakens, discourage staying in bed while awake; use the bed only for sleep",Therapy,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1598,Alzheimer Disease,Disease,Alzheimer's Association,es_3,DISEASES_THERAPY,1,Discourage watching television during periods of wakefulness,Therapy,Alzheimer's Association,es_3,Guideline,https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory,2024/1/1
1599,Alzheimer Disease,Disease,Nederlands Huisartsen Genootschap,es_23,DISEASES_STAGE,,Mild (MMSE 21-26),Stage,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1600,Alzheimer Disease,Disease,Nederlands Huisartsen Genootschap,es_23,DISEASES_STAGE,,Moderate (MMSE 10-20),Stage,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1601,Alzheimer Disease,Disease,Nederlands Huisartsen Genootschap,es_23,DISEASES_STAGE,,Severe (MMSE <10),Stage,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1602,Mild (MMSE 21-26),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_PHENOTYPES,,Memory loss for recent events,Phenotypes,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1603,Mild (MMSE 21-26),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_PHENOTYPES,,Difficulty learning new information,Phenotypes,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1604,Mild (MMSE 21-26),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_PHENOTYPES,,Subtle language problems,Phenotypes,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1605,Moderate (MMSE 10-20),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_PHENOTYPES,,Significant memory loss,Phenotypes,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1606,Moderate (MMSE 10-20),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_PHENOTYPES,,Confusion in daily activities,Phenotypes,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1607,Moderate (MMSE 10-20),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_PHENOTYPES,,Behavioral changes,Phenotypes,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1608,Severe (MMSE <10),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_PHENOTYPES,,Severe memory loss,Phenotypes,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1609,Severe (MMSE <10),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_PHENOTYPES,,Complete dependence on others,Phenotypes,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1610,Severe (MMSE <10),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_PHENOTYPES,,Physical symptoms,Phenotypes,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1611,Mild (MMSE 21-26),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_TREATMENT,,Donepezil Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1612,Mild (MMSE 21-26),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_TREATMENT,,Rivastigmine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1613,Mild (MMSE 21-26),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_TREATMENT,,Galantamine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1614,Moderate (MMSE 10-20),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_TREATMENT,,Donepezil Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1615,Moderate (MMSE 10-20),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_TREATMENT,,Memantine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1616,Mild (MMSE 21-26),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_TREATMENT,,Galantamine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1617,Severe (MMSE <10),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_TREATMENT,,Memantine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1618,Severe (MMSE <10),Stage,Nederlands Huisartsen Genootschap,es_23,STAGE_TREATMENT,,Memantine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1619,Alzheimer Disease,Disease,Nederlands Huisartsen Genootschap,es_23,DISEASES_TREATMENT,-1,Donepezil Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1620,Donepezil Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,DRUG_TREATMENT,,Donepezil,Drug,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1621,Donepezil Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1622,Donepezil Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1623,Alzheimer Disease,Disease,Nederlands Huisartsen Genootschap,es_23,DISEASES_TREATMENT,-1,Galantamine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1624,Galantamine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,DRUG_TREATMENT,,Galantamine,Drug,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1625,Galantamine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1626,Galantamine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1627,Alzheimer Disease,Disease,Nederlands Huisartsen Genootschap,es_23,DISEASES_TREATMENT,-1,Memantine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1628,Memantine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,DRUG_TREATMENT,,Memantine,Drug,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1629,Memantine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,TREATMENT_EFFECTIVENESS,,significant effect on ADL function at 24 weeks,Effectiveness,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1630,Memantine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1631,Alzheimer Disease,Disease,Nederlands Huisartsen Genootschap,es_23,DISEASES_TREATMENT,-1,Rivastigmine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1632,Rivastigmine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,DRUG_TREATMENT,,Rivastigmine,Drug,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1633,Rivastigmine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1634,Rivastigmine Treatment (NHG),Treatment,Nederlands Huisartsen Genootschap,es_23,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Nederlands Huisartsen Genootschap,es_23,Guideline,https://richtlijnen.nhg.org/standaarden/dementie#samenvatting,2020/4/1
1635,Alzheimer Disease,Disease,kaypahoito,es_24,DISEASES_STAGE,,Mild (MMSE 21-26),Stage,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1636,Alzheimer Disease,Disease,kaypahoito,es_24,DISEASES_STAGE,,Moderate (MMSE 10-20),Stage,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1637,Alzheimer Disease,Disease,kaypahoito,es_24,DISEASES_STAGE,,Severe (MMSE <10),Stage,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1638,Mild (MMSE 21-26),Stage,kaypahoito,es_24,STAGE_PHENOTYPES,,Memory loss for recent events,Phenotypes,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1639,Mild (MMSE 21-26),Stage,kaypahoito,es_24,STAGE_PHENOTYPES,,Difficulty learning new information,Phenotypes,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1640,Mild (MMSE 21-26),Stage,kaypahoito,es_24,STAGE_PHENOTYPES,,Subtle language problems,Phenotypes,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1641,Moderate (MMSE 10-20),Stage,kaypahoito,es_24,STAGE_PHENOTYPES,,Significant memory loss,Phenotypes,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1642,Moderate (MMSE 10-20),Stage,kaypahoito,es_24,STAGE_PHENOTYPES,,Confusion in daily activities,Phenotypes,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1643,Moderate (MMSE 10-20),Stage,kaypahoito,es_24,STAGE_PHENOTYPES,,Behavioral changes,Phenotypes,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1644,Severe (MMSE <10),Stage,kaypahoito,es_24,STAGE_PHENOTYPES,,Severe memory loss,Phenotypes,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1645,Severe (MMSE <10),Stage,kaypahoito,es_24,STAGE_PHENOTYPES,,Complete dependence on others,Phenotypes,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1646,Severe (MMSE <10),Stage,kaypahoito,es_24,STAGE_PHENOTYPES,,Physical symptoms,Phenotypes,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1647,Mild (MMSE 21-26),Stage,kaypahoito,es_24,STAGE_TREATMENT,,Donepezil Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1648,Mild (MMSE 21-26),Stage,kaypahoito,es_24,STAGE_TREATMENT,,Rivastigmine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1649,Mild (MMSE 21-26),Stage,kaypahoito,es_24,STAGE_TREATMENT,,Galantamine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1650,Moderate (MMSE 10-20),Stage,kaypahoito,es_24,STAGE_TREATMENT,,Donepezil Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1651,Moderate (MMSE 10-20),Stage,kaypahoito,es_24,STAGE_TREATMENT,,Rivastigmine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1652,Moderate (MMSE 10-20),Stage,kaypahoito,es_24,STAGE_TREATMENT,,Galantamine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1653,Moderate (MMSE 10-20),Stage,kaypahoito,es_24,STAGE_TREATMENT,,Memantine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1654,Severe (MMSE <10),Stage,kaypahoito,es_24,STAGE_TREATMENT,,Donepezil Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1655,Severe (MMSE <10),Stage,kaypahoito,es_24,STAGE_TREATMENT,,Memantine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1656,Alzheimer Disease,Disease,kaypahoito,es_24,DISEASES_TREATMENT,1,Donepezil Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1657,Donepezil Treatment (Kaypahoito),Treatment,kaypahoito,es_24,DRUG_TREATMENT,,Donepezil,Drug,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1658,Donepezil Treatment (Kaypahoito),Treatment,kaypahoito,es_24,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1659,Donepezil Treatment (Kaypahoito),Treatment,kaypahoito,es_24,TREATMENT_POPULATION,,Mild to Severe Alzheimer's Disease (MMSE 1-26),Population,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1660,Alzheimer Disease,Disease,kaypahoito,es_24,DISEASES_TREATMENT,1,Galantamine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1661,Galantamine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,DRUG_TREATMENT,,Galantamine,Drug,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1662,Galantamine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1663,Galantamine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1664,Alzheimer Disease,Disease,kaypahoito,es_24,DISEASES_TREATMENT,1,Memantine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1665,Memantine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,DRUG_TREATMENT,,Memantine,Drug,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1666,Memantine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,TREATMENT_EFFECTIVENESS,,significant effect on ADL function at 24 weeks,Effectiveness,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1667,Memantine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1668,Alzheimer Disease,Disease,kaypahoito,es_24,DISEASES_TREATMENT,1,Rivastigmine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1669,Rivastigmine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,DRUG_TREATMENT,,Rivastigmine,Drug,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1670,Rivastigmine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1671,Rivastigmine Treatment (Kaypahoito),Treatment,kaypahoito,es_24,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1672,Donepezil,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Nausea,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1673,Donepezil,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1674,Donepezil,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1675,Donepezil,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Headache,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1676,Donepezil,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1677,Donepezil,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Agitation,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1678,Rivastigmine,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Gastrointestinal,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1679,Memantine,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Agitation,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1680,Memantine,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Hypertension,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1681,Memantine,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Falls,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1682,Memantine,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1683,Memantine,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Headache,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1684,Galantamine,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Gastrointestinal,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1685,Galantamine,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1686,Galantamine,Drug,kaypahoito,es_24,DRUG_SIDE_EFFECT,,Headache,SideEffect,kaypahoito,es_24,Guideline,https://www.kaypahoito.fi/nix00521,2023/11/12
1687,Alzheimer Disease,Disease,Indian Psychiatric Society,es_25,DISEASES_STAGE,,Mild (MMSE 21-26),Stage,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1688,Alzheimer Disease,Disease,Indian Psychiatric Society,es_25,DISEASES_STAGE,,Moderate (MMSE 10-20),Stage,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1689,Alzheimer Disease,Disease,Indian Psychiatric Society,es_25,DISEASES_STAGE,,Severe (MMSE <10),Stage,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1690,Mild (MMSE 21-26),Stage,Indian Psychiatric Society,es_25,STAGE_PHENOTYPES,,Memory loss for recent events,Phenotypes,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1691,Mild (MMSE 21-26),Stage,Indian Psychiatric Society,es_25,STAGE_PHENOTYPES,,Difficulty learning new information,Phenotypes,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1692,Mild (MMSE 21-26),Stage,Indian Psychiatric Society,es_25,STAGE_PHENOTYPES,,Subtle language problems,Phenotypes,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1693,Moderate (MMSE 10-20),Stage,Indian Psychiatric Society,es_25,STAGE_PHENOTYPES,,Significant memory loss,Phenotypes,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1694,Moderate (MMSE 10-20),Stage,Indian Psychiatric Society,es_25,STAGE_PHENOTYPES,,Confusion in daily activities,Phenotypes,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1695,Moderate (MMSE 10-20),Stage,Indian Psychiatric Society,es_25,STAGE_PHENOTYPES,,Behavioral changes,Phenotypes,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1696,Severe (MMSE <10),Stage,Indian Psychiatric Society,es_25,STAGE_PHENOTYPES,,Severe memory loss,Phenotypes,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1697,Severe (MMSE <10),Stage,Indian Psychiatric Society,es_25,STAGE_PHENOTYPES,,Complete dependence on others,Phenotypes,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1698,Severe (MMSE <10),Stage,Indian Psychiatric Society,es_25,STAGE_PHENOTYPES,,Physical symptoms,Phenotypes,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1699,Mild (MMSE 21-26),Stage,Indian Psychiatric Society,es_25,STAGE_TREATMENT,,Donepezil Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1700,Mild (MMSE 21-26),Stage,Indian Psychiatric Society,es_25,STAGE_TREATMENT,,Rivastigmine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1701,Mild (MMSE 21-26),Stage,Indian Psychiatric Society,es_25,STAGE_TREATMENT,,Galantamine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1702,Moderate (MMSE 10-20),Stage,Indian Psychiatric Society,es_25,STAGE_TREATMENT,,Donepezil Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1703,Moderate (MMSE 10-20),Stage,Indian Psychiatric Society,es_25,STAGE_TREATMENT,,Rivastigmine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1704,Moderate (MMSE 10-20),Stage,Indian Psychiatric Society,es_25,STAGE_TREATMENT,,Galantamine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1705,Moderate (MMSE 10-20),Stage,Indian Psychiatric Society,es_25,STAGE_TREATMENT,,Memantine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1706,Severe (MMSE <10),Stage,Indian Psychiatric Society,es_25,STAGE_TREATMENT,,Donepezil Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1707,Severe (MMSE <10),Stage,Indian Psychiatric Society,es_25,STAGE_TREATMENT,,Memantine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1708,Alzheimer Disease,Disease,Indian Psychiatric Society,es_25,DISEASES_TREATMENT,1,Donepezil Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1709,Donepezil Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,DRUG_TREATMENT,,Donepezil,Drug,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1710,Donepezil Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_DOSAGE,,5mg daily,Dosage,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1711,5mg daily,Dosage,Indian Psychiatric Society,es_25,DOSAGE_DURATION,,Review every 6 months,Duration,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1712,Donepezil Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1713,Donepezil Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_POPULATION,,Mild to severe Alzheimer's Disease (MMSE 1-26),Population,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1714,Alzheimer Disease,Disease,Indian Psychiatric Society,es_25,DISEASES_TREATMENT,1,Galantamine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1715,Galantamine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,DRUG_TREATMENT,,Galantamine,Drug,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1716,Galantamine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_DOSAGE,,8mg daily,Dosage,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1717,8mg daily,Dosage,Indian Psychiatric Society,es_25,DOSAGE_DURATION,,Review every 6 months,Duration,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1718,Galantamine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1719,Galantamine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1720,Alzheimer Disease,Disease,Indian Psychiatric Society,es_25,DISEASES_TREATMENT,1,Memantine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1721,Memantine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,DRUG_TREATMENT,,Memantine,Drug,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1722,Memantine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_DOSAGE,,5mg daily,Dosage,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1723,5mg daily,Dosage,Indian Psychiatric Society,es_25,DOSAGE_DURATION,,Review every 6 months,Duration,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1724,Memantine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_EFFECTIVENESS,,significant effect on ADL function at 24 weeks,Effectiveness,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1725,Memantine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_POPULATION,,Moderate to severe Alzheimer's Disease (MMSE < 20),Population,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1726,Alzheimer Disease,Disease,Indian Psychiatric Society,es_25,DISEASES_TREATMENT,1,Rivastigmine Treatment(Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1727,Rivastigmine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,DRUG_TREATMENT,,Rivastigmine,Drug,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1728,Rivastigmine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_DOSAGE,,3mg daily,Dosage,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1729,3mg daily,Dosage,Indian Psychiatric Society,es_25,DOSAGE_DURATION,,Review every 6 months,Duration,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1730,Rivastigmine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_EFFECTIVENESS,,small significant benefit on cognitive function and ADL,Effectiveness,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1731,Rivastigmine Treatment (Indian Psychiatric Society),Treatment,Indian Psychiatric Society,es_25,TREATMENT_POPULATION,,Mild to moderate Alzheimer's Disease (MMSE 10-26),Population,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1732,Donepezil,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Nausea,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1733,Donepezil,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Vomiting,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1734,Donepezil,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Diarrhea,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1735,Donepezil,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Headache,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1736,Donepezil,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1737,Donepezil,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Agitation,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1738,Rivastigmine,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Gastrointestinal,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1739,Memantine,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Agitation,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1740,Memantine,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Hypertension,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1741,Memantine,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Falls,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1742,Memantine,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1743,Memantine,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Headache,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1744,Galantamine,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Gastrointestinal,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1745,Galantamine,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Dizziness,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1746,Galantamine,Drug,Indian Psychiatric Society,es_25,DRUG_SIDE_EFFECT,,Headache,SideEffect,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1747,Memantine,Drug,Indian Psychiatric Society,es_25,DRUG_PHENOTYPES_CONTRAINDICATION,,Severe renal impairment,Phenotypes,Indian Psychiatric Society,es_25,Guideline,https://journals.lww.com/indianjpsychiatry/fulltext/2018/60003/Clinical_Practice_Guidelines_for_Management_of.7.aspx,2018/2/1
1748,Alzheimer Disease,Disease,Cochrane Library,es_31,DISEASES_WITHDRAWAL,-1,cholinesterase inhibitors_CaroleParsons,Withdrawal,Cochrane Library,es_31,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009081.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/3
1749,Alzheimer Disease,Disease,Cochrane Library,es_31,DISEASES_WITHDRAWAL,0,memantine_CaroleParsons,Withdrawal,Cochrane Library,es_31,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009081.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/3
1750,cholinesterase inhibitors,Drug,Cochrane Library,es_31,DRUG_WITHDRAWAL,,cholinesterase inhibitors_CaroleParsons,Withdrawal,Cochrane Library,es_31,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009081.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/3
1751,memantine,Drug,Cochrane Library,es_31,DRUG_WITHDRAWAL,,memantine_CaroleParsons,Withdrawal,Cochrane Library,es_31,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009081.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/3
1752,cholinesterase inhibitors_CaroleParsons,Withdrawal,Cochrane Library,es_31,WITHDRAWAL_DURATION,,6 months,Duration,Cochrane Library,es_31,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009081.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/3
1753,memantine_CaroleParsons,Withdrawal,Cochrane Library,es_31,WITHDRAWAL_DURATION,,6 months,Duration,Cochrane Library,es_31,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009081.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/3
1754,Alzheimer Disease,Disease,Cochrane Library,es_32,DISEASES_PREVENT,-1,Statins_BernadetteMcGuinness,Prevent,Cochrane Library,es_32,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003160.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2016/1/4
1755,Statins,Drug,Cochrane Library,es_32,DRUG_PREVENT,,Statins_BernadetteMcGuinness,Prevent,Cochrane Library,es_32,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003160.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2016/1/4
1756,Alzheimer Disease,Disease,Cochrane Library,es_33,DISEASES_TREATMENT,0,melatonin_JennyMcCleery,Treatment,Cochrane Library,es_33,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009178.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/11/15
1757,Alzheimer Disease,Disease,Cochrane Library,es_33,DISEASES_TREATMENT,0,melatonin receptor agonist_JennyMcCleery,Treatment,Cochrane Library,es_33,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009178.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/11/15
1758,Alzheimer Disease,Disease,Cochrane Library,es_33,DISEASES_TREATMENT,1,trazodone_JennyMcCleery,Treatment,Cochrane Library,es_33,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009178.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/11/15
1759,Alzheimer Disease,Disease,Cochrane Library,es_33,DISEASES_TREATMENT,1,orexin antagonists_JennyMcCleery,Treatment,Cochrane Library,es_33,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009178.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/11/15
1760,melatonin,Drug,Cochrane Library,es_33,DRUG_TREATMENT,,melatonin_JennyMcCleery,Treatment,Cochrane Library,es_33,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009178.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/11/15
1761,melatonin receptor agonist,Drug,Cochrane Library,es_33,DRUG_TREATMENT,,melatonin receptor agonist_JennyMcCleery,Treatment,Cochrane Library,es_33,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009178.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/11/15
1762,trazodone,Drug,Cochrane Library,es_33,DRUG_TREATMENT,,trazodone_JennyMcCleery,Treatment,Cochrane Library,es_33,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009178.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/11/15
1763,orexin antagonists,Drug,Cochrane Library,es_33,DRUG_TREATMENT,,orexin antagonists_JennyMcCleery,Treatment,Cochrane Library,es_33,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009178.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/11/15
1764,Alzheimer Disease,Disease,Cochrane Library,es_34,DISEASES_TREATMENT,1,Memantine_RupertMcShane,Treatment,Cochrane Library,es_34,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/3/20
1765,Memantine,Drug,Cochrane Library,es_34,DRUG_TREATMENT,,Memantine_RupertMcShane,Treatment,Cochrane Library,es_34,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/3/20
1766,Mild (MMSE 21-26),Stage,Cochrane Library,es_34,STAGE_TREATMENT,,Memantine_RupertMcShane,Treatment,Cochrane Library,es_34,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/3/20
1767,Moderate (MMSE 10-20),Stage,Cochrane Library,es_34,STAGE_TREATMENT,,Memantine_RupertMcShane,Treatment,Cochrane Library,es_34,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/3/20
1768,Severe (MMSE <10),Stage,Cochrane Library,es_34,STAGE_TREATMENT,,Memantine_RupertMcShane,Treatment,Cochrane Library,es_34,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/3/20
1769,Memantine_RupertMcShane,Treatment,Cochrane Library,es_34,TREATMENT_DURATION,,6 months,Duration,Cochrane Library,es_34,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003154.pub6/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/3/20
1770,Alzheimer Disease,Disease,Cochrane Library,es_35,DISEASES_PREVENT,-1,Aspirin_FionnualaJordan,Prevent,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1771,Alzheimer Disease,Disease,Cochrane Library,es_35,DISEASES_PREVENT,-1,cyclo‐oxygenase‐2 and non‐selective NSAID naproxen_FionnualaJordan,Prevent,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1772,Alzheimer Disease,Disease,Cochrane Library,es_35,DISEASES_PREVENT,-1,celecoxib_FionnualaJordan,Prevent,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1773,Alzheimer Disease,Disease,Cochrane Library,es_35,DISEASES_PREVENT,-1,COX‐2 inhibitor rofecoxib_FionnualaJordan,Prevent,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1774,Aspirin,Drug,Cochrane Library,es_35,DRUG_PREVENT,,Aspirin_FionnualaJordan,Prevent,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1775,cyclo‐oxygenase‐2,Drug,Cochrane Library,es_35,DRUG_PREVENT,,cyclo‐oxygenase‐2 and non‐selective NSAID naproxen_FionnualaJordan,Prevent,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1776, non‐selective NSAID naproxen,Drug,Cochrane Library,es_35,DRUG_PREVENT,, non‐selective NSAID naproxen_FionnualaJordan,Prevent,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1777,celecoxib,Drug,Cochrane Library,es_35,DRUG_PREVENT,,celecoxib_FionnualaJordan,Prevent,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1778,COX‐2 inhibitor rofecoxib,Drug,Cochrane Library,es_35,DRUG_PREVENT,,COX‐2 inhibitor rofecoxib_FionnualaJordan,Prevent,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1779,Aspirin_FionnualaJordan,Prevent,Cochrane Library,es_35,PREVENT_DOSAGE,,100mg/day,Dosage,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1780,100mg/day,Dosage,Cochrane Library,es_35,DOSAGE_DURATION,,4.7years,Duration,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1781,cyclo‐oxygenase‐2 and non‐selective NSAID naproxen_FionnualaJordan,Prevent,Cochrane Library,es_35,PREVENT_DOSAGE,,cyclo‐oxygenase‐2 200 mg twice daily,Dosage,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1782,cyclo‐oxygenase‐2 200 mg twice daily,Dosage,Cochrane Library,es_35,DOSAGE_DURATION,,734 days,Duration,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1783,cyclo‐oxygenase‐2 and non‐selective NSAID naproxen_FionnualaJordan,Prevent,Cochrane Library,es_35,PREVENT_DOSAGE,, non‐selective NSAID naproxen 220 mg twice daily,Dosage,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1784, non‐selective NSAID naproxen 220 mg twice daily,Dosage,Cochrane Library,es_35,DOSAGE_DURATION,,734 days,Duration,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1785,celecoxib_FionnualaJordan,Prevent,Cochrane Library,es_35,PREVENT_DOSAGE,,200 mg or 400 mg daily,Dosage,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1786,200 mg or 400 mg daily,Dosage,Cochrane Library,es_35,DOSAGE_DURATION,,17.6 months,Duration,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1787,COX‐2 inhibitor rofecoxib_FionnualaJordan,Prevent,Cochrane Library,es_35,PREVENT_DOSAGE,,25 mg once daily,Dosage,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1788,25 mg once daily,Dosage,Cochrane Library,es_35,DOSAGE_DURATION,,115 weeks,Duration,Cochrane Library,es_35,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011459.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/4/30
1789,Alzheimer Disease,Disease,Cochrane Library,es_36,DISEASES_TREATMENT,0,Cerebrolysin_Shuhui Cui,Treatment,Cochrane Library,es_36,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008900.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/11/11
1790,Cerebrolysin,Drug,Cochrane Library,es_36,DRUG_TREATMENT,,Cerebrolysin_Shuhui Cui,Treatment,Cochrane Library,es_36,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008900.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/11/11
1791,Mild (MMSE 21-26),Stage,Cochrane Library,es_36,STAGE_TREATMENT,,Cerebrolysin_Shuhui Cui,Treatment,Cochrane Library,es_36,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008900.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/11/11
1792,Moderate (MMSE 10-20),Stage,Cochrane Library,es_36,STAGE_TREATMENT,,Cerebrolysin_Shuhui Cui,Treatment,Cochrane Library,es_36,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008900.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2019/11/11
1793,Alzheimer Disease,Disease,Cochrane Library,es_37,DISEASES_TREATMENT,1,Donepezil_CeriEBattle,Treatment,Cochrane Library,es_37,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013306.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/22
1794,Alzheimer Disease,Disease,Cochrane Library,es_37,DISEASES_TREATMENT,1,Galantamine_CeriEBattle,Treatment,Cochrane Library,es_37,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013306.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/22
1795,Alzheimer Disease,Disease,Cochrane Library,es_37,DISEASES_TREATMENT,0,Rivastigmine_CeriEBattle,Treatment,Cochrane Library,es_37,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013306.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/22
1796,Donepezil,Drug,Cochrane Library,es_37,DRUG_TREATMENT,,Donepezil_CeriEBattle,Treatment,Cochrane Library,es_37,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013306.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/22
1797,Galantamine,Drug,Cochrane Library,es_37,DRUG_TREATMENT,,Galantamine_CeriEBattle,Treatment,Cochrane Library,es_37,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013306.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/22
1798,Rivastigmine,Drug,Cochrane Library,es_37,DRUG_TREATMENT,,Rivastigmine_CeriEBattle,Treatment,Cochrane Library,es_37,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013306.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/22
1799,Donepezil_CeriEBattle,Treatment,Cochrane Library,es_37,TREATMENT_DOSAGE,,5 or 10mg/day,Dosage,Cochrane Library,es_37,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013306.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/22
1800,Galantamine_CeriEBattle,Treatment,Cochrane Library,es_37,TREATMENT_DOSAGE,,16~24mg/day,Dosage,Cochrane Library,es_37,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013306.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/22
1801,Rivastigmine_CeriEBattle,Treatment,Cochrane Library,es_37,TREATMENT_DOSAGE,,3~12mg/day,Dosage,Cochrane Library,es_37,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013306.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/2/22
1802,Alzheimer Disease,Disease,Cochrane Library,es_38,DISEASES_PREVENT,0,vitamin B6_JennyMcCleery,Prevent,Cochrane Library,es_38,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011905.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/11/1
1803,Alzheimer Disease,Disease,Cochrane Library,es_38,DISEASES_PREVENT,0,vitamin B12_JennyMcCleery,Prevent,Cochrane Library,es_38,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011905.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/11/1
1804,Alzheimer Disease,Disease,Cochrane Library,es_38,DISEASES_PREVENT,0,vitamin E_JennyMcCleery,Prevent,Cochrane Library,es_38,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011905.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/11/1
1805,vitamin B6,Drug,Cochrane Library,es_38,DRUG_PREVENT,,vitamin B6_JennyMcCleery,Prevent,Cochrane Library,es_38,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011905.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/11/1
1806,vitamin B12,Drug,Cochrane Library,es_38,DRUG_PREVENT,,vitamin B12_JennyMcCleery,Prevent,Cochrane Library,es_38,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011905.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/11/1
1807,vitamin E ,Drug,Cochrane Library,es_38,DRUG_PREVENT,,vitamin E_JennyMcCleery,Prevent,Cochrane Library,es_38,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011905.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/11/1
1808,Alzheimer Disease,Disease,Cochrane Library,es_39,DISEASES_TREATMENT,0,Souvenaid_MarionBurckhardt,Treatment,Cochrane Library,es_39,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011679.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/12/15
1809,Souvenaid,Drug,Cochrane Library,es_39,DRUG_TREATMENT,,Souvenaid_MarionBurckhardt,Treatment,Cochrane Library,es_39,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011679.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/12/15
1810,Mild (MMSE 21-26),Stage,Cochrane Library,es_39,STAGE_TREATMENT,,Souvenaid_MarionBurckhardt,Treatment,Cochrane Library,es_39,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011679.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/12/15
1811,Moderate (MMSE 10-20),Stage,Cochrane Library,es_39,STAGE_TREATMENT,,Souvenaid_MarionBurckhardt,Treatment,Cochrane Library,es_39,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011679.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/12/15
1812,Souvenaid_MarionBurckhardt,Treatment,Cochrane Library,es_39,TREATMENT_DURATION,,16 weeks,Duration,Cochrane Library,es_39,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011679.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2020/12/15
1813,Alzheimer Disease,Disease,Cochrane Library,es_40,DISEASES_TREATMENT,0,Latrepirdine_SarahChau,Treatment,Cochrane Library,es_40,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009524.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/4/21
1814,Latrepirdine,Drug,Cochrane Library,es_40,DRUG_TREATMENT,,Latrepirdine_SarahChau,Treatment,Cochrane Library,es_40,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009524.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/4/21
1815,Mild (MMSE 21-26),Stage,Cochrane Library,es_40,STAGE_TREATMENT,,Latrepirdine_SarahChau,Treatment,Cochrane Library,es_40,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009524.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/4/21
1816,Moderate (MMSE 10-20),Stage,Cochrane Library,es_40,STAGE_TREATMENT,,Latrepirdine_SarahChau,Treatment,Cochrane Library,es_40,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009524.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/4/21
1817,Severe (MMSE <10),Stage,Cochrane Library,es_40,STAGE_TREATMENT,,Latrepirdine_SarahChau,Treatment,Cochrane Library,es_40,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009524.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/4/21
1818,Latrepirdine_SarahChau,Treatment,Cochrane Library,es_40,TREATMENT_DURATION,,26 or 52 weeks,Duration,Cochrane Library,es_40,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009524.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/4/21
1819,Alzheimer Disease,Disease,Cochrane Library,es_41,DISEASES_TREATMENT,1,Rivastigmine_Jacqueline S Birks,Treatment,Cochrane Library,es_41,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/9/22
1820,Rivastigmine,Drug,Cochrane Library,es_41,DRUG_TREATMENT,,Rivastigmine_Jacqueline S Birks,Treatment,Cochrane Library,es_41,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/9/22
1821,Mild (MMSE 21-26),Stage,Cochrane Library,es_41,STAGE_TREATMENT,,Rivastigmine_Jacqueline S Birks,Treatment,Cochrane Library,es_41,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/9/22
1822,Moderate (MMSE 10-20),Stage,Cochrane Library,es_41,STAGE_TREATMENT,,Rivastigmine_Jacqueline S Birks,Treatment,Cochrane Library,es_41,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/9/22
1823,Rivastigmine_Jacqueline S Birks,Treatment,Cochrane Library,es_41,TREATMENT_DOSAGE,,6 to 12 mg/day orally or 9.5 mg/day transdermally ,Dosage,Cochrane Library,es_41,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/9/22
1824,6 to 12 mg/day orally or 9.5 mg/day transdermally ,Dosage,Cochrane Library,es_41,DOSAGE_DURATION,,12~52 weeks,Duration,Cochrane Library,es_41,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001191.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2015/9/22
1825,Alzheimer Disease,Disease,Cochrane Library,es_42,DISEASES_TREATMENT,1,Donepezil_Jacqueline S Birks,Treatment,Cochrane Library,es_42,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/6/18
1826,Donepezil,Drug,Cochrane Library,es_42,DRUG_TREATMENT,,Donepezil_Jacqueline S Birks,Treatment,Cochrane Library,es_42,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/6/18
1827,Mild (MMSE 21-26),Stage,Cochrane Library,es_42,STAGE_TREATMENT,,Donepezil_Jacqueline S Birks,Treatment,Cochrane Library,es_42,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/6/18
1828,Moderate (MMSE 10-20),Stage,Cochrane Library,es_42,STAGE_TREATMENT,,Donepezil_Jacqueline S Birks,Treatment,Cochrane Library,es_42,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/6/18
1829,Severe (MMSE <10),Stage,Cochrane Library,es_42,STAGE_TREATMENT,,Donepezil_Jacqueline S Birks,Treatment,Cochrane Library,es_42,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/6/18
1830,Donepezil_Jacqueline S Birks,Treatment,Cochrane Library,es_42,TREATMENT_DOSAGE,,10mg/day,Dosage,Cochrane Library,es_42,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/6/18
1831,10mg/day,Dosage,Cochrane Library,es_42,DOSAGE_DURATION,,24~26 weeks,Duration,Cochrane Library,es_42,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001190.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2018/6/18
1832,Alzheimer Disease,Disease,Cochrane Library,es_43,DISEASES_TREATMENT,0,Cannabinoid_Dina Bosnjak Kuharic,Treatment,Cochrane Library,es_43,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012820.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/9/17
1833,Cannabinoid,Drug,Cochrane Library,es_43,DRUG_TREATMENT,,Cannabinoid_Dina Bosnjak Kuharic,Treatment,Cochrane Library,es_43,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012820.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/9/17
1834,Mild (MMSE 21-26),Stage,Cochrane Library,es_43,STAGE_TREATMENT,,Cannabinoid_Dina Bosnjak Kuharic,Treatment,Cochrane Library,es_43,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012820.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/9/17
1835,Moderate (MMSE 10-20),Stage,Cochrane Library,es_43,STAGE_TREATMENT,,Cannabinoid_Dina Bosnjak Kuharic,Treatment,Cochrane Library,es_43,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012820.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/9/17
1836,Severe (MMSE <10),Stage,Cochrane Library,es_43,STAGE_TREATMENT,,Cannabinoid_Dina Bosnjak Kuharic,Treatment,Cochrane Library,es_43,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012820.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/9/17
1837,Cannabinoid_Dina Bosnjak Kuharic,Treatment,Cochrane Library,es_43,TREATMENT_DURATION,,3~14 weeks,Duration,Cochrane Library,es_43,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012820.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/9/17
1838,Alzheimer Disease,Disease,Cochrane Library,es_44,DISEASES_THERAPY,0,Dance movement_Vicky Karkou,Therapy,Cochrane Library,es_44,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011022.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2023/8/7
1839,Dance movement,Intervention,Cochrane Library,es_44,INTERVENTION_THERPY,,Dance movement_Vicky Karkou,Therapy,Cochrane Library,es_44,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011022.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2023/8/7
1840,Mild (MMSE 21-26),Stage,Cochrane Library,es_44,STAGE_THERAPY,,Dance movement_Vicky Karkou,Therapy,Cochrane Library,es_44,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011022.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2023/8/7
1841,Alzheimer Disease,Disease,Cochrane Library,es_45,DISEASES_TREATMENT,1,Galantamine_Amanda Wei Yin Lim,Treatment,Cochrane Library,es_45,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2024/11/5
1842,Galantamine,Drug,Cochrane Library,es_45,DRUG_TREATMENT,,Galantamine_Amanda Wei Yin Lim,Treatment,Cochrane Library,es_45,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2024/11/5
1843,Mild (MMSE 21-26),Stage,Cochrane Library,es_45,STAGE_TREATMENT,,Galantamine_Amanda Wei Yin Lim,Treatment,Cochrane Library,es_45,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2024/11/5
1844,Galantamine_Amanda Wei Yin Lim,Treatment,Cochrane Library,es_45,TREATMENT_DOSAGE,,16~24mg/day,Dosage,Cochrane Library,es_45,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2024/11/5
1845,16~24mg/day,Dosage,Cochrane Library,es_45,DOSAGE_DURATION,,6 months,Duration,Cochrane Library,es_45,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001747.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2024/11/5
1846,Alzheimer Disease,Disease,Cochrane Library,es_46,DISEASES_TREATMENT,0,Omega‐3 fatty acid_Marion Burckhardt,Treatment,Cochrane Library,es_46,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2016/4/11
1847,Omega‐3 fatty acid,Drug,Cochrane Library,es_46,DRUG_TREATMENT,,Omega‐3 fatty acid_Marion Burckhardt,Treatment,Cochrane Library,es_46,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2016/4/11
1848,Mild (MMSE 21-26),Stage,Cochrane Library,es_46,STAGE_TREATMENT,,Omega‐3 fatty acid_Marion Burckhardt,Treatment,Cochrane Library,es_46,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2016/4/11
1849,Moderate (MMSE 10-20),Stage,Cochrane Library,es_46,STAGE_TREATMENT,,Omega‐3 fatty acid_Marion Burckhardt,Treatment,Cochrane Library,es_46,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2016/4/11
1850,Omega‐3 fatty acid_Marion Burckhardt,Treatment,Cochrane Library,es_46,TREATMENT_DURATION,,6 months,Duration,Cochrane Library,es_46,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009002.pub3/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2016/4/11
1851,Alzheimer Disease,Disease,Cochrane Library,es_47,DISEASES_TREATMENT,0,Vitamin E_Nicolas Farina,Treatment,Cochrane Library,es_47,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002854.pub5/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2017/4/18
1852,Vitamin E,Drug,Cochrane Library,es_47,DRUG_TREATMENT,,Vitamin E_Nicolas Farina,Treatment,Cochrane Library,es_47,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002854.pub5/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2017/4/18
1853,Vitamin E_Nicolas Farina,Treatment,Cochrane Library,es_47,TREATMENT_DURATION,,6~48 months,Duration,Cochrane Library,es_47,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002854.pub5/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2017/4/18
1854,Alzheimer Disease,Disease,Cochrane Library,es_48,DISEASES_TREATMENT,0,Antipsychotic_Viktoria Mühlbauer,Treatment,Cochrane Library,es_48,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013304.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/12/17
1855,Antipsychotic,Drug,Cochrane Library,es_48,DRUG_TREATMENT,,Antipsychotic_Viktoria Mühlbauer,Treatment,Cochrane Library,es_48,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013304.pub2/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/12/17
1856,Alzheimer Disease,Disease,Cochrane Library,es_49,DISEASES_PREVENT,0,Antihypertensive_Emma L Cunningham,Prevent,Cochrane Library,es_49,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004034.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/5/24
1857,Antihypertensive,Drug,Cochrane Library,es_49,DRUG_PREVENT,,Antihypertensive_Emma L Cunningham,Prevent,Cochrane Library,es_49,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004034.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/5/24
1858,Antihypertensive_Emma L Cunningham,Prevent,Cochrane Library,es_49,PREVENT_DURATION,,1~5 years,Duration,Cochrane Library,es_49,SR,https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004034.pub4/full?highlightAbstract=alzheimer%7Cdisease%7Cdiseas%7Calzheimer%27s%7Calzheim,2021/5/24
1859,Donepezil,Drug,成大指引,es_19,DRUG_DRUG_SYNERGISTIC,,Bethanechol,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1860,Donepezil,Drug,成大指引,es_19,DRUG_DRUG_SYNERGISTIC,,Ketoconazole,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1861,Donepezil,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Oxybutynin,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1862,Donepezil,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Tolterodine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1863,Rivastigmine,Drug,成大指引,es_19,DRUG_DRUG_SYNERGISTIC,,Metoclopramide,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1864,Rivastigmine,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Oxybutynin,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1865,Rivastigmine,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Tolterodine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1866,Galantamine,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Oxybutynin,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1867,Galantamine,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Tolterodine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1868,Galantamine,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Ketoconazole,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1869,Galantamine,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Fluvoxamine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1870,Galantamine,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Fluroxetine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1871,Galantamine,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Paroxetine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1872,Memantine,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Ranitidine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1873,Memantine,Drug,成大指引,es_19,DRUG_DRUG_ANTAGONISTIC,,Cimetidine,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1874,Memantine,Drug,成大指引,es_19,DRUG_DRUG_SYNERGISTIC,,Hydrochlorothiazide,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1875,Memantine,Drug,成大指引,es_19,DRUG_DRUG_SYNERGISTIC,,Sodium bicarbonate,Drug,成大指引,es_19,Guideline,https://health.tainan.gov.tw/lasthealthweb/warehouse/%7B75ACEBBE-480E-4523-83C7-2E13A4A877E4%7Dfile/108train/%E9%99%84%E4%BB%B613_%E5%A4%B1%E6%99%BA%E7%97%87%E7%94%A8%E8%97%A5%E5%AE%89%E5%85%A8%E6%8C%87%E5%B0%8E.pdf,2018/1/1
1876,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_ANTAGONISTIC,,Antimuscarinic drugs,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1877,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_ANTAGONISTIC,,Antimuscarinic drugs,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1878,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_ANTAGONISTIC,,Antimuscarinic drugs,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1879,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_ANTAGONISTIC,,Antipsychotics,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1880,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_ANTAGONISTIC,,Antipsychotics,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1881,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_ANTAGONISTIC,,Antipsychotics,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1882,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_SYNERGISTIC,,Beta-blockers,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1883,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_SYNERGISTIC,,Beta-blockers,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1884,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_SYNERGISTIC,,Beta-blockers,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1885,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_SYNERGISTIC,,Liver enzyme inhibitors,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1886,Donepezil,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_ANTAGONISTIC,,Liver enzyme inducers,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1887,Galantamine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_SYNERGISTIC,,Liver enzyme inhibitors,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1888,Rivastigmine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_SYNERGISTIC,,Metoclopramide,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1889,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_SYNERGISTIC,,Antimuscarinics ,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1890,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_SYNERGISTIC,,Dopaminergics,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1891,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_SYNERGISTIC,,N-methyl-D-aspartate (NMDA)-antagonists ,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1892,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_SYNERGISTIC,,Warfarin,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1893,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_ANTAGONISTIC,,Antipsychotics,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1894,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_ANTAGONISTIC,,Barbiturates,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15
1895,Memantine,Drug,National Institute for Health and Care Excellence,es_20,DRUG_DRUG_ANTAGONISTIC,,Baclofen and dantrolene,Drug,National Institute for Health and Care Excellence,es_20,Guideline,https://www.nice.org.uk/guidance/ta217/chapter/Update-information,2023/1/15